Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1061822] 2022  
PFIZER  CONFIDENTIAL  
Page  1  
 This document and accompanying materials contain confidential information belonging to [COMPANY_007]. Except 
as otherwise agreed to in writing, by [CONTACT_22788], you agree to hold this 
information in confidence and not copy or disclose it to others (except where required by [CONTACT_1289]) 
or use it for unauthorized  purposes.  In the event  of any actual  or suspected  breach  of this obligation,  [COMPANY_007] 
must be promptly notified.   
 
AN INTERVENTIONAL PK, PD, PHASE 1, OPEN- LABEL STUDY TO 
INVESTIGATE PK AND PD OF MULTIPLE- DOSE RITLECITINIB IN CHILDREN 
6 TO LESS THAN 12 YEARS OF AGE WITH SEVERE ALOPECIA AREATA 
Study  Intervention  Number:  PF-06651600 
Study  Intervention  Name:  [CONTACT_773359]:  [ADDRESS_1061823]/CTIS  Number:  NA 
ClinicalTrials.gov ID: NA 
Pediatric  Investigational Plan Number:  EMEA -002451- PIP01 -18 
Protocol Number:  B7981031  
Phase:  1 
Brief  Title: An Open -Label,  Multiple -Dose,  PK, PD Study of Ritlecitinib  in Children  6 
to <12 Years of Age With Severe Alopecia Areata 
 

Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1061824] 2022  
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1061825] OF FIGURES  .................................................................................................................... 8  
1. PROTOCOL  SUMMARY  ..................................................................................................... 9  
1.1. Synopsis  ..................................................................................................................... 9  
1.2. Schema  ..................................................................................................................... 16 
1.3. Schedule of Activities  .............................................................................................. 17 
2. INTRODUCTION ................................................................................................................ 21 
2.1. Study Rationale  ........................................................................................................ 21 
2.2. Background  .............................................................................................................. 21 
2.2.1. Clinical Overview of Ritlecitinib  ................................................................ 23 
[IP_ADDRESS]. Pharmacokinetic Overview of Ritlecitinib  ................................ 23 
[IP_ADDRESS]. Safety  of Ritlecitinib  in Adult and Adolescent  Participants  
With AA (Study B7931015)  .............................................................. 23 
2.3. Benefit/Risk  Assessment  ......................................................................................... 25 
2.3.1. Risk Assessment  ......................................................................................... 26 
2.3.2. Benefit Assessment  ..................................................................................... 27 
2.3.3. Overall Benefit/Risk Conclusion  ................................................................ 27 
3. OBJECTIVES,  ENDPOINTS,  AND ESTIMANDS  ............................................................ 27 
4. STUDY  DESIGN ................................................................................................................. 27 
4.1. Overall  Design  ......................................................................................................... 27 
4.2. S cientific Rationale for Study  Design  ..................................................................... 28 
4.2.1. Patient  Input Into Design  ............................................................................ 28 
4.2.2. Diversity  of Study Population  ..................................................................... 29 
4.2.3. Adjudication Committee  ............................................................................. 29 
4.2.4. E-DMC  ........................................................................................................ 30 
4.2.5. Choice of Contraception/Barrier Requirements  .......................................... 30 
4.3. Justification for Dose  ............................................................................................... 30 
4.4. End of Study Definition  ........................................................................................... 31 
5. STUDY POPULATION ...................................................................................................... 31 
5.1. Inclusion Criteria  ..................................................................................................... 31 
5.2. Exclusion Criteria  .................................................................................................... 33 
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1061826] 2022  
PFIZER  CONFIDENTIAL  
Page  4  
 5.3. Lifestyle  Considerations  ......................................................................................... 35 
5.3.1. Contraception  ............................................................................................. 35 
5.3.2. Meals and Dietary  Restrictions  .................................................................. 36 
5.3.3. Caffeine,  Alcohol, and Tobacco  ................................................................. 36 
5.4. Screen  Failures  ........................................................................................................ 36 
6. STUDY  INTERVENTION(S)  AND  CONCOMITANT  THERAPY  ................................. 37 
6.1. Study Intervention(s) Administered  ........................................................................ 37 
6.1.1. Administration  ............................................................................................ 38 
6.2. Preparation, Handling, Storage, and Accountability  .............................................. 38 
6.2.1. Preparation  and Dispensing  ........................................................................ 40 
6.3. Assignment to Study Intervention  .......................................................................... 40 
6.4. Blinding  .................................................................................................................. 40 
6.5. Study Intervention  Compliance  .............................................................................. 40 
6.5.1. Missed  doses  .............................................................................................. 41 
6.6. Dose  Modification  .................................................................................................. 41 
6.7. Continued Access to  Study Intervention After the End  of the Study  ..................... 42 
6.8. Treatment of Overdose  ........................................................................................... 42 
6.9. Prior and Concomitant Therapy  .............................................................................. 42 
6.9.1. Prohibited Medications  .............................................................................. 42 
6.9.2.
 Prohibited and Permitted  Concomitant CYP3A Inducers, and 
CYP3A  and CYP1A2  Substrates  .................................................................... 43 
[IP_ADDRESS]. Prohibited Concomitant CYP3A  Inducers and Substrates ........ 43 
[IP_ADDRESS]. Permitted  Concomitant CYP3A  Substrates .............................. 44 
[IP_ADDRESS]. Prohibited Concomitant CYP1A2  Substrates  ........................... 44 
[IP_ADDRESS]. Permitted  Concomitant CYP1A2  Substrates  ............................ 44 
7. DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL  ........................................................................... 44 
7.1. Permanent Discontinuation of Study Intervention  ................................................. 44 
7.1.1. Adverse Event  ............................................................................................ 45 
7.1.2. Protocol Deviation  ..................................................................................... 45 
7.1.3. Withdrawal  of Consent  .............................................................................. 45 
7.1.4. Pregnancy  ................................................................................................... 46 
7.1.5. COVID- 19 .................................................................................................. 46 
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1061827] 2022  
PFIZER  CONFIDENTIAL  
Page  5  
 7.1.6. Temporary  Discontinuation  ......................................................................... 46 
7.2. Participant Discontinuation/Withdrawal From the Study  ....................................... [ADDRESS_1061828] to Follow- Up ................................................................................................... 47 
8. STUDY  ASSESSMENTS AND PROCEDURES  ............................................................... 48 
8.1. Administrative  and Baseline Procedures  ................................................................. 48 
8.1.1. Baseline Procedures  .................................................................................... 49 
8.1.2. Telehealth  Visits  .......................................................................................... 49 
8.1.3. Home  Health  Visits  ..................................................................................... 50 
8.2. Efficacy  Assessments  .............................................................................................. 50 
8.2.1. Rater Qualifications  .................................................................................... 50 
8.3. Safety Assessments  .................................................................................................. 51 
8.3.1. Physical  Examinations  ................................................................................ 51 
8.3.2. Vital Signs  ................................................................................................... 52 
[IP_ADDRESS]. Blood Pressure and Heart  Rate .................................................. 52 
8.3.3. Clinical Safety  Laboratory Assessments ..................................................... 52 
[IP_ADDRESS]. Alternative Facilities for Clinical Safety  Laboratory  
Assessment  ......................................................................................... 53 
8.3.4. Pregnancy Testing  ....................................................................................... 53 
8.3.5. Suicidal Ideation  and Behavior Risk Monitoring  ........................................ 54  
8.4. Adverse Events, Serious Adverse Events, and Other  Safety  Reporting  .................. 54 
8.4.1. Time  Period  and Frequency for Collecting  AE and SAE  Information ........ 54 
[IP_ADDRESS]. Reporting SAEs to [COMPANY_007] Safety  ............................................... 55 
[IP_ADDRESS]. Recording Nonserious AEs and SAEs  on the CRF ................... 55 
8.4.2. Method of Detecting  AEs and SAEs  ........................................................... 55 
8.4.3. Follow- Up of AEs and SAEs  ...................................................................... 55 
8.4.4. Regulatory Reporting Requirements for SAEs  ........................................... 56 
8.4.5. Environmental Exposure, Exposure During Pregnancy or 
Breastfeeding, and Occupational Exposure  ..................................................... 56 
[IP_ADDRESS]. Exposure During Pregnancy  ...................................................... 56 
[IP_ADDRESS]. Exposure During Breastfeeding  ................................................. 58 
[IP_ADDRESS]. Occupational Exposure  .............................................................. 59 
8.4.6. Cardiovascular  and Death  Events  ................................................................ 59 
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1061829] 2022  
PFIZER  CONFIDENTIAL  
Page  6  
 8.4.7. Disease Related  Events  and/or Disease  Related  Outcomes Not 
Qualifying  as AEs or SAEs  ............................................................................. [ADDRESS_1061830]  ............................................................. 59 
[IP_ADDRESS]. Lack of Efficacy  ....................................................................... 59 
8.4.9. Medication  Errors  ....................................................................................... 59 
8.5. Pharmacokinetics .................................................................................................... 60 
8.6. Genetics  .................................................................................................................. 62 
8.6.1. Specified  Genetics  ...................................................................................... 62 
8.7. Pharmacodynamics ................................................................................................. 62 
8.7.1. Biomarkers  ................................................................................................. 62 
8.7.2. Samples for Interferon  Gamma -Induced Protein  10 (IP-10) Analysis  ....... 63 
8.7.3. Samples for Fluorescence- Activated  Cell Sorting Analysis (T Cell,  B 
Cell,  and NK Cell Subsets)  ............................................................................. 63 
8.7.4. Specified Gene Expression (RNA) Research  ............................................ 63 
8.7.5. Specified  Protein  Research  ......................................................................... 63 
8.7.6. Specified  Metabolomic  Research  ............................................................... 63 
8.7.7. Retained  Research  Samples  for Biomarkers  .............................................. 63 
8.8. Immunogenicity  Assessments ................................................................................ 63 
8.9. Health  Economics  ................................................................................................... 63 
9. STA TISTICAL CONSIDERATIONS  ................................................................................ 63 
9.1. Statistical Hypothesis  ............................................................................................. 63 
9.2. Analysis Sets ........................................................................................................... 64 
9.3. Statistical Analyses  ................................................................................................. 64 
9.3.1. Safety  Analyses  .......................................................................................... 64 
9.3.2. Pharmacokinetic Analyses ......................................................................... 64 
9.3.3. Pharmacodynamic Analyses ...................................................................... 65 
9.3.4. Taste Assessment Analyses ....................................................................... 65 
9.4. Interim Analyses  ..................................................................................................... 65 
9.5. Sample Size Determination  .................................................................................... 65 
10. SUPPORTING DOCUMENTATION AND OPERATIONAL  
CONSIDERATIONS .......................................................................................................... 66 
10.1. Appendix 1: Regulatory, Ethical, and  Study Oversight Considerations  ............... 66 
10.1.1. Regulatory and Ethical Considerations  .................................................... 66 
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1061831] 2022  
PFIZER  CONFIDENTIAL  
Page  7  
 [IP_ADDRESS]. Reporting of Safety Issues and Serious Breaches of the 
Protocol or ICH GCP  ........................................................................ 66 
10.1.2. Financial Disclosure  ................................................................................. 67 
10.1.3. Informed  Consent/Assent Process  ........................................................... 67 
10.1.4. Data  Protection  ......................................................................................... 68 
10.1.5. Committees  Structure  ............................................................................... 69 
[IP_ADDRESS]. Data  Monitoring Committee  ................................................... 69 
10.1.6. Dissemination  of Clinical Study  Data ...................................................... 69 
10.1.7. Data  Quality  Assurance  ............................................................................ 70 
10.1.8. Source Documents  ................................................................................... 71 
10.1.9. Study and Site Start and Closure  .............................................................. 72 
10.1.10. Sponsor’s Medically Qualified Individual  ............................................. 73 
10.2. Appendix 2: Clinical Laboratory Tests  ................................................................ 74 
10.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow- Up, and Reporting  ..................................................................... 75 
10.3.1. Definition  of AE ....................................................................................... 75 
10.3.2. Definition  of an SAE ................................................................................ 76 
10.3.3. Recording/Reporting and Follow- Up of AEs and/or SAEs  During  
the Active Collection Period  ........................................................................... 77 
10.3.4. Reporting of SAEs  ................................................................................... 81 
10.4. Appendix 4: Contraceptive and Barrier  Guidance  ................................................ 82 
10.4.1. Male Participant Reproductive Inclusion Criteria  ................................... 82  
10.4.2. Female Participant  Reproductive Inclusion Criteria  ................................ 82 
10.4.3. Woman  of Childbearing Potential  ............................................................ 83 
10.4.4. Contraception Methods  ............................................................................ 84 
10.5. Appendix 5: Liver  Safety:  Suggested Actions and Follow- Up Assessments ....... 86 
10.6. Appendix 6: Kidney Safety  Monitoring Guidelines  ............................................. 88 
10.6.1. Laboratory  Assessment of Change in Kidney  Function and 
Detection of Kidney Injury  ............................................................................. 88 
10.6.2. Age-Specific  Kidney Function Calculation Recommendation  ................ 88 
10.6.3. Adverse  Event  Grading  for Kidney Safety  Laboratory  
Abnormalities  .................................................................................................. 88 
10.7. Appendix 7: Prohibited  Concomitant Medications That May Result  in DDI ....... 89 
10.8. Appendix 8: Country- Specific Requirements  ........................................................ 91 
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1061832] 2022  
PFIZER  CONFIDENTIAL  
Page  8  
 10.8.1. [LOCATION_009]  ........................................................................................................ 91 
10.8.2. Japan  ......................................................................................................... 91 
[IP_ADDRESS]. Reporting Requirements  .......................................................... 91 
[IP_ADDRESS]. Reporting Procedure  ................................................................ 92 
10.9. Appendix 9: Hepatitis  B testing  algorithm and full eligibility  criteria  .................. 93 
10.10. Appendix 10 – SALT .......................................................................................... 94 
10.11. Appendix 11 – C- SSRS ....................................................................................... 95 
10.12. Appendix 12 – CDRS -R ...................................................................................... 96 
10.13. Appendix 13.1 – PROMIS® Parent Proxy Short Form v2.0 – Anxiety 8a .......... 97 
10.13.1. Appendix 13.2 – PROMIS® Parent Proxy Short Form v2.0 –  
Depressive Symptoms 6a ................................................................................. 97 
10.14. Appendix 14 - BRIEF®2  ..................................................................................... 98 
10.15. Appendix 15 - Modified CDLQI  ......................................................................... 99 
10.16. Appendix 16 - WISC -V ..................................................................................... 100 
10.17. Appendix 17: Abbreviations  .............................................................................. [ADDRESS_1061833] OF FIGURES  
Figure 1. Study Visits and Procedures  ...................................................................... 16 
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1061834] 2022  
PFIZER  CONFIDENTIAL  
Page  9  
 1. PROTOCOL SUMMARY 
1.1. Synopsis  
Protocol Title:  An Interventional PK, PD, Phase 1, Open -Label  Study to Investigate PK and 
PD of Multiple -Dose Ritlecitinib in Children 6 to less than 12 Years of Age With Severe 
Alopecia Areata  
Brief  Title: An Open -Label,  Multiple -Dose,  PK, PD Study of Ritlecitinib  in Children  6 to 
<12 Years of Age With  Severe Alopecia Areata 
Regulatory Agency  Identification  Number(s):  
 
US IND Number:  [ADDRESS_1061835]/CTIS  Number:  NA 
ClinicalTrials.gov  ID: NA 
Pediatric Investigational Plan Number:  EMEA -002451 -PIP01 -18 
Protocol Number:  B7981031  
Phase:  Phase  1 
 
Rationale:  
The PK assessments from this study are necessary  to support ritlecitinib  dose selection  in 
subsequent studies in children aged 6 to <12 years of age. 
Objectives,  Endpoints,  and Estimands:  
 
Objectives  Endpoints  
Primary:  Primary:  
• To characterize  the PK of ritlecitinib  in children  with 
AA 6 to <12 years of age.  • AUC 24 on Day 7 
Secondary:  Secondary:  
• To further  characterize  the PK of ritlecitinib  in children 
with AA 6 to <12 years of age.  • Cmax, Tmax, CL/F,  VZ/F and t½ on Day 7 
• To characterize  the PD of ritlecitinib  in children  with 
AA 6 to < 12 years of age.  • Change  from  baseline  in interferon  gamma  IP-10 and 
lymphocyte subsets (T cell, B cell, and NK cells) on 
Day 7  
• To evaluate  the safety  and tolerability  of ritlecitinib  in 
children with AA 6 to < 12 years of age.  • Treatment -emergent  adverse  events  (AEs).  
• Treatment  related  AEs.  
• SAEs  and AEs leading to discontinuation.  
• Clinically  significant abnormalities in vital signs.  
• Clinically  significant abnormalities in clinical  laboratory 
values.  
• To assess the overall palatability, acceptability, and 
tolerability of the proposed age appropriate  
formulation in children with AA aged  6 to <12 years of 
age. • Taste  assessment  
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1061836] 2022  
PFIZER  CONFIDENTIAL  
Page  10  
 Overall Design:  
Study B7981031 is a single- group, uncontrolled, open-label, interventional PK, PD study to 
estimate the systemic exposures of [ADDRESS_1061837] 12 children  with AA, 6 
to <[ADDRESS_1061838] 4 participants 6 to < 9 years of age.  
The dose to be studied was derived by [CONTACT_773322]. Participants in this study will receive ritlecitinib for  
7 days, with PK, PD assessments on Day 7. 
Number of Participants:  
Twelve evaluable participants will be required to complete the PK analysis at Day 7. At 
sponsor’s discretion, up to 3 participants  may be replaced  if they do not provide a full set of 
evaluable PK data.  
Note:  "Enrolled" means an agreement  has been  obtained of a participant  and their legally 
authorized representative(s)to participate in a clinical study following completion of the informed consent process and assignment to study intervention. A participant will be considered  enrolled if the informed  consent is not withdrawn  prior to participating  in any 
study activity. Potential participants who are screened for the purpose of determining eligibility for the study, but do not participate in the study, are not considered enrolled. 
Study Population:  
Th
e full set of inclusion/exclusion criteria  is provided  in Section  5 of the protocol. 
Key inclusion and exclusion criteria are listed below: 
Key Inclusion Criteria  
Participants  must meet  the following  key inclusion  criteria  to be eligible  for enrollment into 
the study: 
1. Children  who are 6 to <12 years old at the time of the screening  visit.  Refer  to 
(Section 10.4) for reproductive criteria for male and female participants.  
2. A diagnosis of severe AA, including AT and AU, with ≥50%  scalp  hair loss due to AA 
(ie, a SALT score ≥50) at both the Screening and Baseline visits, without evidence of 
terminal hair regrowth within the previous 12 months. 
3. Fo r  study participants  in the EU/[LOCATION_006] only:  
History  of clinical  response failure  to AA treatment (such  as topi[INVESTIGATOR_2855],  off-label 
pharmacologic, or hairpi[INVESTIGATOR_773298])  
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1061839] 2022  
PFIZER  CONFIDENTIAL  
Page  11  
 AND EITHER:  
a. P articipants with a history  of psychological counseling for AA (as evidenced  by 
[CONTACT_773323]) in the past year prior to Screening  
Participants are eligible if current psychosocial impairment is confirmed by 
[CONTACT_773324]: 
• PROMIS®  Parent  Proxy  Anxiety Symptoms: T- score 60- 70 
• PROMIS®  Parent  Proxy  Depressive Symptoms: T- score  60-70 
• BRIEF®2  (BRI,  ERI, CRI): T- score  60-70 on any one of the 3 components of the 
BRIEF®2.  
• M odified CDLQI  (score of > 7) 
OR 
b. P articipants with no history  of psychological counseling for AA in the past year prior 
to Screening  
In order to be eligible for  this study, participants must: 
• Have a T -score of 60-70 on any one of the 3 instruments (PROMIS®Anxiety 
Symptoms or PROMIS® -Depressive Symptoms or any one of the 3 components 
of BRIEF®2) 
• Complete  at least 5 psychological counseling sessions  for AA prior to Screening  
• Be re-evaluated  after completion  of the psychological counseling and have  a 
T-score of 60 -70 on any one of the three instruments 
(PROMIS®Anxiety - Symptoms  or PROMIS® -Depressive Symptoms  or any one 
of the 3 components of BRIEF®2) 
Key Exclusion Criteria  
Participants  with any of the following  characteristics/conditions will be excluded:  
1. Conditions that may impact  absorption or metabolism of IP (eg, celiac disease, 
cholecystectomy or gastrectomy). 
2. History (one or more epi[INVESTIGATOR_1841]) of CMV, varicella, herpes zoster (shingles) or 
disseminated  herpes simplex. A history  of uncomplicated herpes simplex  is not 
exclusionary.  
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1061840] 2022  
PFIZER  CONFIDENTIAL  
Page  12  
 3. Other  medical  or psychiatric  condition  (including recent  [within  the past year]  or active 
suicidal ideation/behavior) that may increase the risk of study participation or, in the 
investigator’s  judgment, make the participant inappropriate for the study, including but 
not limited to: 
• For participants in the EU/[LOCATION_006] with scores of >70 on the PROMIS® or any component of the BRIEF®2,  or with previous history  of suicidal  behaviors in the past 
5 years, “Yes” answer for events that occurred in the past [ADDRESS_1061841] be performed and documented by a qualified mental health professional to assess whether it is safe to participate in the trial. 
• For participants in the US and other non- EU/[LOCATION_006] countries with a previous history  of 
suicidal behaviors in the past 5 years, “Yes” answer for events that occurred in the past [ADDRESS_1061842]  be performed 
and documented by a qualified mental health professional to assess whether it is safe 
to participate in the trial.  
• For participants  in the US and other non- EU/[LOCATION_006]  countries: Clinically  significant 
depression per the CDRS- R (T-score ≥40).  
• History  of or presence of any current  major psychiatric disorder that is not explicitly 
permitted in the inclusion/exclusion criteria.  
4. Renal  dysfunction defined  as: 
• eCrCl  normalized  to BSA:  confirmed  eCrCl  <60 mL/min/1.73  m
2 based  on 
Modified Schwartz equation (pediatric patients 2 to < 12 years of age). See 
Appendix 6. 
5. Hepatic dysfunction defined  as: 
• Total  bilirubin  >1.5 × ULN  (except  for Gilbert’s  syndrome)  
• AST  >1.5 × ULN  
• ALT  >1.5 × ULN  
6. Hematologic  abnormalities  defined as: 
• Absolute neutrophil count <1.2 × 109/L (<1200/mm3) 
• Hemoglobin <11.0 g/dL  
• Platelet  count <150 × 109/L (<150,000/mm3) 
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1061843] 2022  
PFIZER  CONFIDENTIAL  
Page  13  
 • Absolute lymphocyte count of <0.8 ×109 /L (<800/mm3) 
7. Investigator site staff directly involved in the conduct of the study and their family 
members,  site staff otherwise supervised  by [CONTACT_093],  and sponsor and sponsor 
delegate employees directly involved in the conduct of the study and their family members.  
Study Arms and Duration:  
The study includes a screening  period of up to 28 days, a 7- day interventional period, and a 
28 day follow-up period. The duration of study participation for each participant is approximately 9 weeks. 
 
Study Intervention(s)  
Intervention  Name  [CONTACT_773360]  (PF-06651600)  
Arm  Name  
(group of participants receiving  a specific 
treatment or no treatment)  Active study medication  
Unit  Dose  Strength(s)  20 mg 
Route of Administration  Oral 
Use Experimental  
IMP or NIMP/AxMP  IMP 
 
 
Arm  Title experimental  
Arm  Type  experimental  
Arm Description  Participants will receive 
study medication, 20 mg 
per day, for 7 days.  
 
Statistical Methods:  
A sample  size of 12 participants  should provide adequate pharmacokinetic information.  The 
plasma PK parameters will be listed and summarized descriptively. Plasma concentrations 
will be listed and summarized descriptively by [CONTACT_458097]. Individual participant and median profiles of the plasma concentration -time data will be plotted using 
actual and nominal times, respectively. Median profiles will be presented on both linear- linear and log -linear scales.  
Taste acceptability  assessment  questionnaire will be included. Taste acceptability  will be 
listed and summarized descriptively (frequencies and percentages).  
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1061844] 2022  
PFIZER  CONFIDENTIAL  
Page  14  
 Ethical Considerations:  
As of August 2022, there  are no systemic treatments  approved by [CONTACT_773325].  
Review  of the treatment  guidelines and recommendations indicates that a number  of off-label 
therapi[INVESTIGATOR_773299], disease 
extent and disease duration. However, there is neither a cure for AA nor is there a therapy convincingly demonstrated to induce and sustain drug- free remission long term.  
1,2,3,4,[ADDRESS_1061845] been published and presented. 
6,7,8 
The results of previous studies of ritlecitinib in adults and adolescents support the investigation of ritlecitinib for AA in children and there is a favorable benefit-risk profile to support the rationale for this study. Taking into account the measures to minimize risk to 
participants, the potential risks associated with ritlecitinib are justified by [CONTACT_773326]. 
This is a short -term PK, PD study and therefore no benefit to the participants is expected. 
However, participants who complete this study will qualify to be screened for a planned long- term,  open -label  study, where  ritlecitinib  (active  dose only) will be provided for up to 
3 years.  Dose  selection  for this planned study will be based  on results  from Study B7981031, 
and thus enrollment into the planned long- term study  will not occur immediately  after Study 
B7981031.  
The clinical  data from the B7981015 study of ritlecitinib  in adults  and adolescents (≥ 12 to 
<18 years of age) with AA indicate that ritlecitinib has a favorable benefit/risk profile for treatment of adults and adolescents with AA for up to 48 weeks. It provides meaningful clinical benefit in this serious disease with no approved treatment options in pediatric populations, and it has an acceptable  safety  profile.  The benefit of evaluating ritlecitinib  in 
children is additionally supported by [CONTACT_773327]. 
Participants and their parents/legal guardians will be expected to commit time for 
participating in this study as they will be required to visit the study  site 3 times during the 
study (Screening, Day 1 and Day 7). Day 7 PK assessments will occur over an 8-hour period. 
Also,  participants may experience some  discomfort  while  undergoing study  assessments such 
as blood draws. 
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1061846] 2022  
PFIZER  CONFIDENTIAL  
Page  15  
 Blood samples will be  collected  at Screening  and Day 7 as follows:  
 
Study  Visit  Test Screening  EOT  
Screening  Hematology  0.5 ml 0.5 ml 
Blood  chemistry  0.5 ml 0.5 ml 
QFT 1 ml  
IP-10 1 ml 1 ml 
Lymphocyte  subsets  2 ml 2 ml 
Hepatitis  B/C 2 ml  
HIV 2 ml  
Pregnancy  (serum)  2 ml  
Day 7 PK  5 ml (5 × 1 ml) 
Total  Blood  Volume  [ADDRESS_1061847] be within the allowed limits for this patient population (see Section 8.1 for details).  
In addition, participants  must agree  to use appropriate  contraception methods if  applicable, 
not use prohibited medications,  and to follow  protocol specified  lifestyle  guidelines during 
the study (see Appendix 4 and Appendix 7 for details).  
The study incorporates  mitigations  against known risks  to ensure the safety  of the trial 
participants.  
Ritleci tinib (PF-06651600) 
Protocol B7981031  
PFIZER CONFIDENTIAL  
Page [ADDRESS_1061848] 2022  
 
1.2. Schema 
Figure 1. Study V isits and Procedure s 
 
28-35 Days  
28 Safety 
 Days   Follow-up 
  
        
Screening  e, 
- 
t 
Beginning  of Treatment  End of Treatment  End of 
Study  
 
Visit  Types:  
• 
Treatment) or Early Tennination  
 
• Telephone  visits: Days 2, 4, 6 and  End of Study  
 
•  
 
 
• 
 
 
 
 
 Office  visits:  Screening,  Day 1 (Beginning  of treatment) , Day 7 (End  of e, e, e, e, e, e, 
N w   
VI 0\  
--.) 
      
 
Ritleci tinib (PF-06651600) 
Protocol B [ADDRESS_1061849] 2022  
PFIZER  CONFIDENTIAL  
Page  17  
  
1.3. Schedule of Activities 
The SoA  table prov ides an overview of  the protocol visits and procedures. Refer to the STUDY ASSESSMENTS AND 
PROCEDURES  sectio n of the protocol for detailed infonna tion on each procedure and assessmen t requi red for complia nce with the 
protocol.  
The investigator  may schedule visits (unplanned visits) in addition to those listed  in the SoA table,  in order to conduct  evaluations  or 
assess ment s requi red to protect the  well-being of the  paiiic ipant. These visits may be conducted in the clinic, by [CONTACT_756] , or in the 
paiiicipant's home. 
 
Visit Identifier  
Abbreviations  used  in 
this table may be found 
in Aooendix 17  Sc1·een T1·eatment Period F/U 
End of Study Notes 
 Up to 28 
days 
before 
Day 1 Day 
1 
Base 
line Day 
2 Day 
3 Day 
4 Day 
5 Day 
6 Day7 
EOT Day 35 to 42 • Day relative to strut of study intervention (Day  1). 
• F/U contact  [CONTACT_773328]  28 to 35 days  after 
administration of the final  dose  of study intervention.  
• If treatment is discontinued prior  to Day 7, an EOT  visit must be  conducted, 
followed by [CONTACT_773329] [ADDRESS_1061850] dose.  
• If paiticipation  in the study and treatment  ai·e discontinued at the  saine time, 
the EOT and EOS visits will be conducted together.  • All screening  should be done  <[ADDRESS_1061851] dose. 
In-office  visits X X      X  • In addition to specified in-office and telephone visits, additional in -office , 
telephone  or in-home visits may be conducted at any time during the study 
for safety  reasons or for reasons related  to dosing or PK, PD blood draws.  Telephone visits    X  X  X  X 
Informed 
consen t/assent X         • Infonned consent and pa1ticipant assent  should be obtained prior  to 
undergoing  any study-specific  procedures.  
Screen  for 
inclusion/exclu sion 
criteria X          
Demographics  X          
Registration/ 
drug assiIDunen t  X        At registration , the pa1ticipant  enrollment number  and treatment  alloca tion are 
assiQtled . 
Medical Histon and Phvsical Examin ation 
Medical  history X          
Full physical 
examination  X          
Ritleci tinib (PF-06651600) 
Protocol B [ADDRESS_1061852] 2022  
PFIZER  CONFIDENTIAL  
Page  18  
  
Visit Identifier  
Abbreviations used  in 
this table may  be found 
in Annendix 17  Screen T1·eatment Period F/U 
End of Study Notes 
 Up to 28 
days 
before 
Day 1 Day 
1 
Base 
line Day 
2 Day 
3 Day 
4 Day 
5 Day 
6 Day7 
EOT Day 35 to 42 • Day relative  to strut of study intervention  (Day  1). 
• F/U contact  [CONTACT_773328]  28 to 35 days after 
adminis tration of the fina l dose of study  intervention.  
• If treatment is discontinue d prior to Day 7, an EOT  visit must be  conducted, 
followed by [CONTACT_773329] 28- [ADDRESS_1061853] dose.  
• If paiticipation  in the study and treatment  ai·e discontinued at the  saine time , 
the EOT and EOS visits will be conducted together . • All screening  should be done <[ADDRESS_1061854] dose. 
Brief  physical 
examination   X      X   
Weillh t/Heillh t X          
Vital siQtl s X       X  heart  rate, blood pressure 
Contracep tion check  (if 
aoolicable ) X X      X   
Laborntor y Assessments 
Hemato lo2v X       X   
Blood chemistry  X       X   
QFT , Hepa titis B and 
C,HIV X          
Urine  dipstick  X         Urinaly sis will  be perfonned by [CONTACT_773330] (source document ) ; if an abnonna l or symptoma tic result is 
observed, the samp le will be  sent to the local laboratory. Micros copic analysi s 
and urine culture will be  performed if s uspi[INVESTIGATOR_773300] 
!Positive for nitrite  and/or  leukoc yte esterase or if otherv. •ise clinically  indicated.  
Pregnancy  test X X      X  Required  only in females of childbearing potential.  Semm at screening , urine at 
baseline and EOT . 
See Section 8.3.4 for additional  info1mation)  
Study Inte1 -vention and Other Treatments 
Study  medication 
intervention  
admini stration  X X X X X X X   
Prior /concomitant 
treatment (s) X X X  X  X X X  
Ritleci tinib (PF-06651600) 
Protocol B [ADDRESS_1061855] 2022  
PFIZER  CONFIDENTIAL  
Page  19  
  
Visit Identifier  
Abbreviations used  in 
this table may be found 
in Annendix 17  Screen T1·eatment Period F/U 
End of Study Notes 
 Up to 28 
days 
before 
Day 1 Day 
1 
Base 
line Day 
2 Day 
3 Day 
4 Day 
5 Day 
6 Day7 
EOT Day 35 to 42 • Day relative  to strut of study  intervention  (Day  1). 
• F/U contact  [CONTACT_773331]  28 to 35 days after 
administration  of the final dose of study intervention.  
• If treatment is discontinued prior to Day 7, an EOT  visit must be  conducted, 
followed by [CONTACT_773332] 28- [ADDRESS_1061856] dose.  
• If paiticipation  in the study and treatment  ai·e discontinued at the  saine time , 
the EOT and EOS visits will be conducted together . • All screening  should be done  <[ADDRESS_1061857] dose. 
Assess ments 
SALT score X X         
Taste Assessmen t 
Questionnaire         X   
Seriou s and nonseriou s 
AE monitoring  X X X  X  X X X  
C-SSRS suicidal 
ideation and beha vior 
risk assessment X          
CDRS -R X         US and other  non-EU/[LOCATION_006]  coun tries 
PROMIS ® Pai·ent 
Proxy  X         EU/[LOCATION_006]  only  
BRIEF ®2 (BRI, ERi, 
CRI)  X         EU/[LOCATION_006]  only  
Modified  CDLOI  X         EU/[LOCATION_006]onlv  
WISC -V (Wech sler 
Intelligence Scale for 
Children  - 5th edition)  X        EU/[LOCATION_006] only  
Documentation  of 
psychological 
counseling  X         EU/[LOCATION_006] only  
Phannacokinetic Assess ment s See laboratory  manual.  
Ritlecitinib (PF-0665 1600) 
Protocol B [ADDRESS_1061858] 2022  
Page  20  
  
Visit Identifier  
Abbreviations used  in 
this table may be found 
in Annendix I7  Screen T1·eatment Period F/U 
End of Study Notes 
 Up to 28 
days 
before 
Day 1 Day 
1 
Base 
line Day 
2 Day 
3 Day 
4 Day 
5 Day 
6 Day7 
EOT Day 35 to 42 • Day relative to strut of study intervention (Day  1). 
• F/U contact  [CONTACT_773331]  28 to 35 days after 
administration of the final  dose  of study intervention.  
• If treatment is discontinued prior  to Day 7, an EOT  visit must be  conducted, 
followed by [CONTACT_773329] [ADDRESS_1061859] dose.  
• If paiticipation  in the study and treatment  ai·e discontinued at the saine time, 
the EOT and EOS visits will be conducted toge ther. • All screening should be done  <[ADDRESS_1061860] dose. 
PK samples        X  • PK samples required at Day 7 at Ohr (pre-dose), and 0.5 hr, 1 hr, 3 hrs, and 
8 hrs after dosing. 
• PK will be conducted  only on Day 7 and only if no more  than one dose was 
missed between  Davs 2 and 5. 
          •  
Phannacodvnamic assess ment s 
IP-10 X       X  • To be collected  before dose. 
• IP-10 will be collected  at screening  and Day 7 only. If  treatmen t is 
discontin ued, IP-10 will not be collected  on Dav 7. 
Lymphocyte  subsets (T 
cells, B cells , and NK 
cells)  X       X  • Lymphocyte subsets will be collect ed at screening and Day 7 only. If 
treatmen t is discontinued, lymphocyte subse ts will not be collected  at Day 7. 

Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1061861] 2022  
PFIZER  CONFIDENTIAL  
Page  21  
 2. INTRODUCTION 
2.1. Study Rationale  
The PK and PD assessments from this study are necessary  to support ritlecitinib  dose 
selection in subsequent studies in children 6 to <12 years of age. 
2.2. Background  
AA is a chronic relapsing T -cell mediated autoimmune disorder characterized by [CONTACT_105] - 
scarring hair loss affecting children and adults across all ages, races, and sexes.9,10 AA is 
associated  with other  immune diseases including asthma,  allergic  rhinitis,  atopic dermatitis, 
and autoimmune diseases such as thyroiditis and vitiligo.10 
 
CD8 + T cells, NK cells, and mast cells are involved in the pathogenesis of AA. The possible 
inflammatory  pathways in AA include cytokines from  the TH1 axis, including IFN α, IFN γ, 
and IFN γ -IP-10.11,[ADDRESS_1061862] shown that IL-2 and IL-15 play a role in the 
initiation of auto -reactive CD8 + cells that attack hair follicles.13 IL-12 and IL -23 may also 
play a role in the pathogenesis of AA.  
Clinical presentation of AA can be limited  to small,  circular  patches of scalp  hair loss (patchy 
hair loss, alopecia focalis), involve complete loss of hair on the scalp (AT), or total loss of 
hair on the scalp and body (AU). AA involving 50% or greater scalp hair loss, including AT and AU, is considered an advanced form of alopecia, according to the US National Alopecia Areata Foundation.
[ADDRESS_1061863] common form of AA which may develop 
into the more  extensive and often  treatment- resistant forms  of AA, especially  with earlier age 
of onset.15 It is estimated that AA affects as many as 6 to 7 million individuals in the US10 
and 147 million worldwide.14 
 
The spontaneous remission rates for AA patients presenting with <50% scalp hair loss (patchy hair loss, alopecia focalis) are 30 -50% within the first 6-12 months of disease onset, 
and 66% of the patients  will show complete  regrowth  of hair within  5 years.
16 The likelihood 
of complete regrowth spontaneously with AT or AU is less than 10%.[ADDRESS_1061864] of AA on the psychological health of both adult and pediatric patients with AA, including impairment in self- esteem, increased 
incidence of anxiety and depressive disorders  and other psychological conditions,
20,21,22,23,24 
problems with social relations,25 decreased HRQoL and QoL, as well as the QoL of their 
families.26,27,28,29,30,31,32,33,34 
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1061865] been affected more in dimensions of total problems, anxiety/depression, and internalizing/externalizing  syndromes. Children  with AA 
were also less likely to have experienced positive life events in the year prior to exhibiting AA signs.
25 
In addition to experiencing a significant mental health burden, children with AA report experiencing  other negative impacts to their QoL.  Specifically,  75% of children  aged  15-19 
years reported instances of effects on QoL, 50% reported that the disease limited their participation  in activities,  40% reported instances of bullying, and 35% reported  that others 
noticed and commented on their condition. Rates of decrement in QoL, limitations on participation in activities, and bullying were heightened in older children aged 15- 19 years 
compared to younger children.
35 
Given  the finding that complete  scalp  hair loss with duration >[ADDRESS_1061866] onset has been reported to correspond to an increased lifetime risk of extensive disease. Differences in treatment responses are not expected for adolescent  versus adult AA patients  as suggested in 2 reports  of tofacitinib  (off-label  use).  
8,36 
No meaningful differences were observed between treatment responses in adults and adolescents treated with ritlecitinib in Study B7981015 (reference [COMPANY_007] data on file).  
As of August 2022, there  are no systemic treatments  approved by [CONTACT_773325].  
Review  of the treatment  guidelines and recommendations indicates that a number of off-label 
therapi[INVESTIGATOR_773299], disease extent, and disease duration. However, there is neither a cure for AA, nor is there a therapy convincingly demonstrated to induce and sustain drug- free remission long term.
1-5 
Previous studies  (B7981015 and B7981032) included adult and pediatric  populations 
between ages of 12 to < [ADDRESS_1061867]  data supporting a dose selection  for pediatric 
patients 6 to < 12 years of age.  
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1061868] 2022  
PFIZER  CONFIDENTIAL  
Page  23  
 2.2.1. Clinical Overview  of Ritlecitinib  
 
The ritlecitinib  AA clinical  development program was  designed to  evaluate the efficacy  and 
safety  of ritlecitinib  treatment in  adolescent  (12 to  <18 years of  age)  and adult (≥18 years  of 
age) AA patients with ≥50% scalp hair loss (as assessed by [CONTACT_773333]), including AT and AU.  
 
The clinical development program of ritlecitinib in AA was a global program including 21 
Phase 1 studies, 4 Phase 2/3 studies in AA and 1 Phase 2b study in vitiligo. The study in vitiligo  is relevant  for the evaluation of safety  in AA due to similarities  between  the AA and 
vitiligo populations (including disease pathophysiology, age distribution, comorbidities), similar ritlecitinib  dosing regimens  to those in the AA studies,  and similar safety  monitoring 
in vitiligo and AA study protocols. 
 
As of 30 May 2022, ritlecitinib  had been  orally  administered  to 1630 participants in these 5 
Phase 2/3 clinical efficacy and safety studies, as follows: B7931005 (Phase 2a in AA), B7981015 (Phase 2b/3 in AA), B7981037 (Phase 2a AA study to provide additional data regarding  the clinical  relevance of the axonal dystrophy finding in the 9-month dog toxicity 
study), B7981032 (Phase 3 long-term safety study in AA), and B7981019 in vitiligo. 
 
[IP_ADDRESS]. Pharmacokinetic  Overview of Ritlecitinib  
 
The PK profile of ritlecitinib  is characterized by  [CONTACT_773334], rapid elimination (t
½ of 
~2 hours) and is approximately dose proportional. Steady state generally appears to have been reached by [CONTACT_2006] 4 for the QD regimens and Day 6 for the BID regimens based on similar median  trough (pre-dose) ritlecitinib  beyond Day 6. Ritlecitinib  has been  evaluated  at 
single oral doses ranging from 5 mg to 800 mg and multiple oral doses ranging from 50 mg to 400 mg QD and at 100 mg and 200 mg BID for 14 days. The clearance mechanisms for ritlecitinib in humans appear to be primarily by [CONTACT_89411]. Less than 10% of ritlecitinib is excreted unchanged in the urine. 
 
[IP_ADDRESS]. Safety  of Ritlecitinib  in Adult  and Adolescent  Participants  With  AA (Study 
B7931015)  
 
B7981015 was a Phase 2b/3, randomized, double blind, placebo controlled, dose ranging study to investigate  ritlecitinib  in both adolescent  (≥12 to <18 years old) and adult (≥18  years 
old) participants  with ≥50%  scalp  hair loss due to AA. The study had a maximum duration of 
approximately 57 weeks. This included an up to 5-week Screening period, a 48- week 
treatment period, and a 4 -week follow up period. The treatment period was comprised of a 
placebo -controlled period that included a 4-week loading phase and a 20- week maintenance 
phase, followed by a 24- week extension phase.  
 
E
ligible participants were randomized to blinded ritlecitinib and matching placebo in a 
2:2:2:2:1:1:1  (200 mg/50 mg, 200 mg/30 mg, 50 mg, 30 mg, 10 mg, placebo-200 mg/50  mg, 
and placebo- 50 mg, respectively) manner for a total of 7 treatment sequences.  
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1061869] 2022  
PFIZER  CONFIDENTIAL  
Page  24  
 The study randomized 105 adolescents (12 to 17 years of age) and the distribution  of 
adolescents across treatment groups was similar.  
 
Ritlecitinib  200/50 mg, 200/30 mg, 50 mg and 30 mg were  significantly  superior to placebo 
at Week 24 on clinician -assessed and patient -reported endpoints related to scalp hair 
regrowth (including response based on absolute SALT ≤20, response based on absolute 
SALT ≤10, and PGI -C response). Exposure response modelling based on SALT ≤20 and 
SALT ≤10 response at Week  24 showed  a positive relationship  between  dose and response. 
Ritlecitinib 200/50 mg, 200/30 mg, 50 mg and 30 mg were also nominally superior to placebo at Week 24 in producing improvement in eyebrows and eyelashes. Continued improvement in efficacy endpoints was seen between Week 24 and Week 48.  
 
Overall  efficacy  was similar  in adolescents (12 to <18 years of age) and adults (≥18 years  of 
age).  
 
The proportion of participants who experienced all- causality TEAEs was similar across 
treatment groups up to Week 24 (placebo-controlled period) and up to Week 48 (overall). The most frequently reported TEAEs in any group included nasopharyngitis, headache, and upper respi[INVESTIGATOR_2826].  Up to week  24, the incidence of nasopharyngitis, folliculitis, 
urticaria, dizziness, upper respi[INVESTIGATOR_773301] (particularly 200/50 mg and 200/30 mg) than placebo.  
Most  TEAEs  were  mild to moderate  in severity. Fourteen participants  experienced  16 SAEs 
up to Week 48: 
 
• 200/50 mg (4 participants): appendicitis; empyema  and sepsis;  invasive lobular breast 
carcinoma, spontaneous abortion.  
• 200/30 mg (2 participants): appendicitis; chemical poisoning  and suicidal behavior.  
• 50 mg (2 participants): breast cancer; pulmonary  embolism.  
• 30 mg (1 participant): diverticulitis.  
• 10 mg (2 participants): suicidal behavior; eczema.  
• Placebo -200/50 mg: no SAEs.  
• Placebo -50 mg (3 participants): spontaneous abortion; conversion disorder; heavy 
menstrual bleeding. These treatment -emergent SAEs were all reported during the 
Placebo -Controlled Period. 
 
Of the 16 SAEs,  12 were  considered  by [CONTACT_773335]. 
The 4 SAEs that were considered related to study intervention in the opi[INVESTIGATOR_773302] (both in 1 participant); breast cancer; and eczema. There were no deaths in the study.  
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1061870] weeks of the study, there were slight, transient 
decreases in hemoglobin and small, variable changes in neutrophil and leukocyte levels. Small, early decreases in platelets were observed with ritlecitinib treatment; these levels remained stable up to Week 48. Dose- dependent early decreases in absolute lymphocyte 
levels, CD3 (T lymphocytes) and T lymphocyte subsets (CD4 and CD8) were observed. There was a dose-dependent early decrease in CD16/56 (NK cells), particularly in groups who had received  a 200 mg loading dose of PF‑[ADDRESS_1061871], bilirubin, or alkaline phosphatase. The incidence of elevation in hepatic enzymes was low and not dose dependent. Up to Week  48, there  were  no potential Hy’s  law cases.  
 
Overall,  ritlecitinib  was safe and well-tolerated  in the adolescent population. In general,  there 
was a lower  proportion of adolescent  participants  with SAEs,  severe AEs and AEs of interest 
relative  to adult (≥18 years  of age) participants.  The TEAEs  suggest there  are no risks  unique 
to adolescents, except for a higher frequency of acne in the adolescent patients which is not unexpected considering that acne is generally more common in adolescents than adults. 
 
For a complete description  and results  of this study, please refer to the current version of the 
ritlecitinib IB.  
 
2.3. Benefit/Risk  Assessment  
 
More detailed information about the known and expected benefits and risks and reasonably expected  adverse events of ritlecitinib  may be found in the current version  of the IB, which  is 
the SRSD for this study. 
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1061872] 2022  
PFIZER  CONFIDENTIAL  
Page  26  
 2.3.1. Risk  Assessment  
 
Potential  Risk  of Clinical 
Significance  Summary  of Data/Rationale 
for Risk  Mitigation Strategy  
Study  Intervention(s) Ritlecitinib  
• viral reactivation  
• serious infections and 
opportunistic  infections  
• malignancy and lymphoproliferative  disorders  
• thromboembolism  
• dermatologic  effects  (eg. rash, 
acne, folliculitis, urticaria)  
• reduction  in platelet  count  and 
lymphocyte count  Clinical  experience with other 
JAK inhibitors  
Ritlecitinib  clinical  studies 
(B7931005, B7981015, B7981019,  B7981032,  and 
B7981037)  and pre-clinical 
studies  Exclusion  of participants  at risk 
Short duration of treatment  
Safety  labs at screening,  baseline and 
EOT Visit  
Study  Procedures  blood  collection  for PK 
Extravasation,  bruising,  local 
discomfort  Collection  of [ADDRESS_1061873] one 
venipuncture.  
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1061874] 2022  
PFIZER  CONFIDENTIAL  
Page  27  
 2.3.2. Benefit  Assessment  
No immediate therapeutic benefits are expected from participation in this study. However, 
after completion of this study, participants will qualify  to be screened  for the planned 3-year, 
long-term, open-label (active dose only) Study B7981028. Dose selection for this planned study will be based on results from Study B7981031, and thus enrollment into the planned long-term study will not occur immediately after Study B7981031. Also, data collected in this study will support dose selection for the planned pediatric safety and efficacy Study B7981027.  
2.3.3. Overall Benefit/Risk Conclusion  
Taking into account the short treatment  duration and the measures to minimize  the risk to 
study participants (through the inclusion/exclusion criteria and safety monitoring), the potential risks identified in association with ritlecitinib are expected to be minimal and justified by [CONTACT_773336].  
3. OBJECTIVES,  ENDPOINTS,  AND  ESTIMANDS  
 
Objectives  Endpoints  
Primary:  Primary:  
• To characterize  the PK of ritlecitinib  in children  with 
AA 6 to <12 years of age.  • AUC 24 on Day 7 
Secondary:  Secondary:  
• To further  characterize  the PK of ritlecitinib  in children 
with AA 6 to <12 years of age.  • Cmax, Tmax, CL/F,  VZ/F and t½ on Day 7 
• To characterize  the PD of ritlecitinib  in children  with 
AA 6 to <12 years of age.  • Change  from  baseline  in interferon  gamma  IP-10 and 
lymphocyte subsets (T cell, B cell, and NK cells) on 
Day 7  
• To evaluate  the safety  and tolerability  of ritlecitinib  in 
children with AA 6 to <12 years of age. • TEAE  
• Treatment  related  AEs.  
• Serious AEs (SAEs) and AEs leading to discontinuation.  
• Clinically significant abnormalities in vital signs.  
• Clinically  significant abnormalities in clinical  laboratory 
values.  
• To assess the overall palatability, acceptability, and 
tolerability of the proposed age appropriate  
formulation in children with AA aged  6 to <12 years of 
age. • Taste  assessment  
 
4. STUDY DESIGN 
4.1. Overall Design  
This is an interventional, PK, PD, Phase 1, open label study in children 6 to less than 12 years of age with ≥50%  scalp  hair loss due to AA. The purpose of the study  is to collect  data 
to support dose selection for subsequent studies in the same population. 
Participants  will be screened  and, if all eligibility  criteria  are met, will receive the first dose 
of IP within 28 days after the screening visit.  
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1061875] 2022  
PFIZER  CONFIDENTIAL  
Page  28  
 Participants  will receive 20 mg ritlecitinib  in one dose, daily, for 7 consecutive days. On 
Day 7 (EOT) blood samples for PK will be collected at:  
• 0 hr (pre-dose)  
• 0.5 hr, 
• 1 hr, 
• 3 hrs, and 
• [ADDRESS_1061876] dose of ritlecitinib.  
4.2. Scientific Rationale for Study Design  
The PK assessments from this  study are necessary  to support ritlecitinib  dose selection  in 
subsequent studies in children 6 to <12 years of age. The systemic exposure assessments from this study will provide information on whether the selected dose for children 6 to  
<12 years old provides exposures similar to the proposed dose for adolescents and adults. The PD endpoints of IP-10 and lymphocyte subsets will be assessed  to understand if there  is 
any difference in PD responses between children 6 to less than 12 years of age, and adults and adolescents. The open- label, 7 -day study design has been reviewed by  [CONTACT_773337], respectively. 
The 20 mg  dose selected  is predicted  to provide exposures in  6 to <12 year  old children, 
similar to the 30 mg dose in adults and adolescents. 
 
The study is designed as a 7 day multiple dose study. Multiple doses are necessary for 
evaluating steady  state PK because ritlecitinib  has non stationary  PK and steady  state is 
achieved after >[ADDRESS_1061877] dose. 
4.2.1. Pa tient Input Into Design  
Surveys of children and parents were  conducted to evaluate preferences and feasibility  of the 
study, including study drug administration, blood draws, and clinic visit duration. 
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1061878] to race, ethnicity, and age to ensure the study population is representative  of the patient population that will use study intervention in clinical  practice.  
4.2.3. Adjudication  Committee  
This protocol  will use an independent endpoint adjudication  committee  to determine  whether 
certain investigator- reported events meet the definition of disease- related safety endpoints, 
using predefined endpoint criteria. Further information about this endpoint adjudication committee is provided in a charter, including a description of the scope of the committee’s responsibilities, the process and definitions to be utilized by [CONTACT_773338], 
and communication plan including timelines. 
The following adjudication committees  are used for the B798 program:  
• Opportunistic Infection  Review  Committee  (OIRC),  
• Cardiovascular  Event Adjudication Committee (CVEAC),  
• Malignancy  Adjudication Committee  (MAC),  and 
• Neurosafety  Event Adjudication Committee  (NSEAC).  
Events requiring submission to an adjudication/review committee  will be identified  by: 
• [COMPANY_007]  Study Team  or designee during the review  of participant data listings  or by  
• Site monitors during routine monitoring of participant’s study records 
Additional types of events for review  and adjudication may be identified  by [CONTACT_4618].  
The [COMPANY_007]  Study Team  or designee will notify the study site of any such events should they 
be identified. The [COMPANY_007]  Study Team  or designee will provide a listing  of specific documents needed to 
support event adjudication by [CONTACT_488064]/Review Committees. Obtaining and 
submitting the documentation will be the responsibility of the study site.  
Event documentation will vary with the event requiring  adjudication and may include (but 
not limited to): hospi[INVESTIGATOR_8838], operative reports, clinic notes, ECGs, diagnostic tests, pathology reports, autopsy reports and death certificate information, as applicable.  
Review  of redacted  copi[INVESTIGATOR_773303], where ethically and scientifically justified and permitted by [CONTACT_427], to ensure completeness and quality of event documentation prior to submission to Adjudication/Review Committees.  
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1061879] 2022  
PFIZER  CONFIDENTIAL  
Page  30  
 4.2.4. E-DMC  
This study will use an E -DMC. The E -DMC will be responsible for ongoing monitoring of 
the safety of participants in the study according to the charter. The recommendations made 
by [CONTACT_941] E- DMC will be forwarded to the appropriate authorized [COMPANY_007] personnel for review 
and final decision. [COMPANY_007]  will communicate such decisions,  which  may include summaries of 
aggregate analyses of endpoint events and of safety  data that are not endpoints, to regulatory 
authorities and investigators, as appropriate. 
Composition of the E- DMC  and the processes under which  the E-DMC operates will be 
documented in the E- DMC charter.  
4.2.5. Choice of Contraception/Barrier Requirements  
Human  reproductive safety  data for ritlecitinib  are limited  and not enough to evaluate  the risk 
for treatment related birth defects. In animal studies (rats and rabbits) fetotoxicity and fetal 
malformations were observed at exposures equivalent to 49 to 55 times the MRHD. No developmental toxicity was observed at exposures equivalent to 12 to 16 times the MRHD. Although the suspi[INVESTIGATOR_773304], the use of a highly effective method of contraception in WOCBP is required (see Appendix 4).  
The definition of WOCBP  is provided in Section  10.4.3. 
4.3. Justification for Dose 
The selected  dose for Study B7981031 is 20 mg QD. The rationale  for this dose selection  is 
as follows.  
 
Study B7981015 was performed  in adults and adolescents and evaluated  5 dosing regimens 
of ritlecitinib: 
• 50 mg and 30 mg with and without a loading dose of 200 mg  
• A 10 mg dose without loading dose.  
The results from the above study indicated that the 10 mg dose did not differentiate from placebo, while the doses of 50 and 30 mg with and without loading dose demonstrated significant  efficacy  over placebo. The 50 mg dose (without loading dose) was identified  as 
the regimen with optimal benefit:risk for adults and adolescents for registration.  
 
The dose determination  to support dosing in this study was based  on the following 
considerations:  
 
1. The systemic exposure data generated  in B7981015 for adult and adolescent participants 
were utilized to derive the dose recommendations for children (6 to <12 years of age) using population PK modeling and simulation analysis. 
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1061880] 2022  
PFIZER  CONFIDENTIAL  
Page  31  
 2. The dose selected  for children 6 to <12 years of age in Study B7981031 is expected  to 
provide lower exposures than the 50 mg dose in the B7981015 study in adults and 
adolescents.  
The dose of 20 mg selected for evaluation in this PK, PD study is predicted to provide exposures in children 6 to <[ADDRESS_1061881] scheduled  procedure 
(as shown in the SoA ) for the last participant in the trial, globally.  
5. STUDY POPULATION 
This study can fulfill its objectives only if appropriate participants are enrolled, including participants across diverse and representative racial and ethnic backgrounds. If a prescreening tool is utilized for study recruitment purposes, it will include collection of information  that reflects  the enrollment of a diverse participant population including, where 
permitted under local regulations, age, sex, race, and ethnicity. The following eligibility criteria are designed to select participants for whom participation is considered appropriate for the present study  and subsequent screening in the planned long- term study. All relevant 
medical and nonmedical conditions should be taken into consideration when deciding whether a particular participant is suitable for this protocol.  
Prospective approval of protocol deviations to recruitment and enrollment  criteria,  also 
known as protocol waivers or exemptions, is not permitted. 
[COMPANY_007] will review eligibility criteria verified by [CONTACT_773339]. The enrollment approval process will be initiated for a participant after an informed consent document has been signed and the investigator or qualified designee has assessed the participant as eligible. The enrollment approval will be based on review of CRF/system data.  
There  are no enrollment minimums or maximums in any  country. 
5.1. Inclusion  Criteria  
Participants  are eligible  to be included in the study  only if all of the following  criteria  apply:  
Age and Sex: 
1. Participants  who are 6 to <12 years old at the time of the screening  visit.  Refer  to 
(Section 10.4) for reproductive criteria for male and female participants.  
Disease Characteristics:  
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1061882] 2022  
PFIZER  CONFIDENTIAL  
Page  32  
 2. A diagnosis of severe AA, including AT and AU, with ≥50%  scalp  hair loss due to AA 
(ie, a SALT score of  ≥50)  at both the Screening  and Baseline visits,  without evidence of 
terminal hair regrowth within the previous 12 months. 
Other  Inclusion  Criteria:  
3. Fo r  study participants  in the EU/[LOCATION_006] only:  
History  of clinical  response failure  to AA treatment (such  as topi[INVESTIGATOR_2855],  off-label 
pharmacologic, or hairpi[INVESTIGATOR_773298])  
AND  
a. P articipants with a history  of psychological counseling for AA (as evidenced  by 
[CONTACT_773323]) in the past year prior to Screening  
Participants are eligible if current psychosocial impairment is confirmed by 
[CONTACT_773324]: 
• PROMIS®  Parent  Proxy  Anxiety Symptoms: T- score 60- 70 
• PROMIS®  Parent  Proxy  Depressive Symptoms: T- score 60- 70 
• BRIEF®2  (BRI,  ERI, CRI): T- score  60-70 on any one of the 3 components of the 
BRIEF®2.  
• M odified CDLQI  (score  of >7) 
NOTE:  For T-scores higher than 70 (PROMIS  and BRIEF)  see exclusion criterion  7. 
OR 
b. P articipants with no history of psychological counseling for AA in the past year prior 
to Screening  
In order to be eligible for  this study, participants must: 
• Have a T -score of 60-70 on any one of the 3 instruments (PROMIS®-Anxiety 
Symptoms or PROMIS® -Depressive Symptoms or any one of the 3 components 
of BRIEF®2) 
• Complete  at least 5  psychological counseling sessions for  AA prior  to Screening  
• Be re-evaluated  after completion  of the psychological counseling and have  a 
T-score of 60 -70 on any one of the three instruments (PROMIS®-Anxiety 
Symptoms or PROMIS® -Depressive Symptoms or any one of the 3 components 
of BRIEF®2) 
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1061883] 2022  
PFIZER  CONFIDENTIAL  
Page  33  
 NOTE:  For T-scores higher than 70 (PROMIS  and BRIEF)  see exclusion criterion  7. 
5.2. Exclusion Criteria  
Participants  are excluded from the  study  if any of the  following  criteria apply:  
Medical Conditions:  
1. A known congenital cause of AA, other systemic diseases that may cause hair loss (eg, 
lupus erythematosus, thyroiditis,  systemic  sclerosis,  lichen  planus, etc) or other etiology 
of hair loss (eg, telogen effluvium, androgenetic alopecia, etc). 
2. Conditions that may impact  absorption or metabolism  of IP (eg, celiac disease, 
cholecystectomy or gastrectomy). 
3. Pre-existing  hearing loss, or sudden hearing  loss, or middle  or inner ear disease such as 
chronic otitis media, cholesteatoma, Meniere’s disease, laby[CONTACT_344105], or other auditory condition that is considered acute, fluctuating or progressive. If hearing loss is due to acute otitis media, participants can be rescreened at a later date, once the condition resolves.  
4. Any present malignancies or history of malignancies, history of any lymphoproliferative disorder such as EBV related lymphoproliferative disorder, history  of lymphoma, history 
of leukemia,  or signs and symptoms suggestive of current lymphatic  or lymphoid disease,  
5. Active  autoimmune disorder  (other than AA),  known immunodeficiency  disorder, or a 
first degree relative with a hereditary immunodeficiency.  
6. History (one or more epi[INVESTIGATOR_1841]) of CMV, varicella, herpes zoster (shingles) or disseminated  herpes simplex. A history  of uncomplicated herpes simplex  is not 
exclusionary.  
7. Other  medical  or psychiatric  condition  (including recent  [within  the past year]  or active 
suicidal ideation/behavior) that may increase the risk of study participation or, in the investigator’s judgment, make the participant inappropriate for the study, including but not limited to: 
• For participants in the EU/[LOCATION_006] with scores of >70 on the PROMIS® or any 
component of the BRIEF®2,  or with previous history  of suicidal  behaviors in the past 
5 years (“Yes” answer for events that occurred in the past 5 years) to any of the suicidal behavior items of the C -SSRS or with any lifetime history of serious or 
recurrent suicidal behavior, a risk assessment must be performed and documented by a qualified mental health professional to assess whether it is safe to participate in the trial. 
• For participants in the US and other non- EU/[LOCATION_006] countries with a previous history  of 
suicidal behaviors in the past 5 years (“Yes” answer for events that occurred in the past 5 years)  to any of the suicidal behavior items  of the C- SSRS or with any lifetime  
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1061884] be  performed 
and documented by a qualified mental health professional to assess whether it is safe 
to participate in the trial.  
• For participants  in the US and other non- EU/[LOCATION_006] countries: Clinically  significant 
depression per the CDRS- R (T-score ≥40).  
• History  of or presence of any current  major psychiatric disorder that is not explicitly 
permitted in the inclusion/exclusion criteria.  
8. Trisomy  21 (EU/[LOCATION_006] only)  
Prior/Concomitant Therapy:  
9. Current use of any prohibited concomitant medication(s)  or history  of discontinuation of 
treatment with a JAK inhibitor due to a treatment related adverse event. Refer to  
Section  6.9. 
Prior/Concurrent Clinical Study Experience:  
10. Previous administration  with an investigational product (drug or vaccine)  within  30 days 
(or as determined by [CONTACT_19970]) or [ADDRESS_1061885] dose of 
study intervention used in this study (whichever is longer). 
Diagnostic Assessments:  
11. Any laboratory abnormality that may increase the risk of study participation or, in the 
investigator’s  judgment, make the participant inappropriate  for the study, including but 
not limited to the following: 
• Renal  dysfunction defined  as: 
• eCrCl  normalized  to BSA:  Confirmed  eCrCl  <60 mL/min/1.73  m2 based  on 
Modified Schwartz equation (pediatric patients 2 to < 12 years of age). See 
Appendix 6. 
• Hepatic dysfunction defined  as: 
• Total  bilirubin  >1.5 × ULN  (except  for Gilbert’s syndrome)  
• AST  >1.5 × ULN  
• ALT  >1.5 × ULN  
• Hematologic  abnormalities  defined as: 
• Absolute neutrophil count <1.2 × 109/L (<1200/mm3) 
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1061886] 2022  
PFIZER  CONFIDENTIAL  
Page  35  
 • Hemoglobin <11.0 g/dL 
• Platelet  count <150 × 109/L (<150,000/mm3) 
• Absolute lymphocyte count of <0.8 × 109 /L (<800/mm3) 
• Any infection  requiring hospi[INVESTIGATOR_059], parenteral  antimicrobial therapy or judged 
to be opportunistic by [CONTACT_622667] [ADDRESS_1061887] (or equivalent) performed within [ADDRESS_1061888] dose of IP. QFT (or equivalent) test should be performed  during screening  if not performed  within  past 3 months (see 
Appendix 9).  
NOTE:  participants  may be rescreened  after the infection  resolves.  
12. Current or recent history of clinically significant severe, progressive, or uncontrolled renal (including but not limited to active renal disease or recent kidney stones), hepatic, hematological, gastrointestinal, metabolic, endocrine (particularly thyroid disease which can be associated with hair loss), pulmonary, cardiovascular, psychiatric, immunologic/rheumatologic or neurologic disease; or have any other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the 
risk associated with study participation or investigational product administration, or interfere with the interpretation of study results; or in the opi[INVESTIGATOR_22747] (or designee), the participant is inappropriate for entry into this study, or unwilling/unable  to comply with study  procedures and lifestyle  requirements.  Significant 
trauma or major surgery within [ADDRESS_1061889] dose of IP is also exclusionary.  
Other Exclusion Criteria: 
13. Not up to date with all age appropriate vaccines, including 2- dose vaccination for 
varicella,  or vaccination with attenuated  live vaccine within  [ADDRESS_1061890] of the study and their family members.  
5.3. Lifestyle Considerations  
5.3.1. Contraception  
The investigator or their designee,  in consultation with the participant,  will confirm that the 
participant  is utilizing  an appropriate method of contraception for the individual participant  
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1061891] 2022  
PFIZER  CONFIDENTIAL  
Page  36  
 and their partner(s) from the permitted list of contraception methods (see Appendix 4, 
Section 10.4.4) and will confirm that the participant has been instructed in its consistent and 
correct use.  At time points indicated in the SoA , the investigator or designee will inform the 
participant  of the need  to use an highly effective  contraception consistently  and correctly  and 
document the conversation and the participant’s affirmation in the participant’s chart.  
Participants need to affirm their consistent and correct use of at least [ADDRESS_1061892] the participant to call immediately  if the 
selected contraception method is discontinued and document the requirement to use an alternate protocol -specified method, including if the participant will no longer use abstinence 
as the selected  contraception  method, or if pregnancy is known or suspected  in the participant 
or partner.  
5.3.2. Meals and Dietary  Restrictions  
There  are no restrictions  regarding  food or drink either before or after dosing. Participants 
should follow their regular diet. 
5.3.3. Caffeine,  Alcohol, and Tobacco  
 
Participants  will abstain  from  ingesting caffeine or xanthine containing products (tea, coffee, 
cola drinks, etc) during the study (from [ADDRESS_1061893] dose until collection of final 
PK sample). Use of alcohol or tobacco is not expected in this population and should not be used during the study. 
 
5.4. Screen  Failures  
Screen  failures  are defined  as participants  who consent to participate  in the clinical  study but 
are not subsequently enrolled in the study. A minimal set of screen failure information is required to ensure transparent  reporting  of screen  failure  participants  to meet  the CONSORT 
publishing requirements and to respond to queries from regulatory authorities. Minimal information includes demography, screen failure details, and any SAE. 
Screen  failure data are  collected and remain  as source and  are not reported on the CRF.  
Individuals who do not meet  the criteria  for participation  in this study (screen  failure)  may 
be rescreened if at the time of the initial screening they were disqualified for not meeting exclusion criteria 12, 10, 11 (hematological abnormalities only) or 16 and 17. 
Participants  not meeting  inclusion criteria  12, 10, 11 may be rescreened  after the exclusion 
interval is over as follows: 
• exclusion criterion  # 12 – 30 days for significant  trauma,  
• exclusion criterion  # 10 – 30 days or 5 half- lives  for investigational products  
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1061894] 2022  
PFIZER  CONFIDENTIAL  
Page  37  
 • exclusion criterion # 11 – hematological abnormalities  
Participants  not meeting  exclusion criteria  11 may be rescreened  after the exclusion interval 
is over and the infection resolves as follows: 
• exclusion criterion  # 11 – infection  requiring hospi[INVESTIGATOR_773305] – 
3 months after the infection resolves 
• exclusion criterion  # 11 – Active  acute or chronic infection  requiring treatment  – 28 
days after the infection resolves (exception for superficial skin infections – 7 days 
after the infection resolves)  
At the rescreening  visit,  all screening  procedures must be repeated,  including lab tests and all 
other eligibility criteria must be met.  
6. STUDY INTERVENTION(S)  AND CONCOMITANT THERAPY 
Study interventions  are all prespecified  investigational and medical  devices,  and other 
interventions (eg, surgical and behavioral) intended to be administered to the study 
participants during the study conduct. 
 
For the purposes of this protocol, study  intervention  refers  to ritlecitinib.  The daily  dose is 
[ADDRESS_1061895] up to 7 days. 
6.1. Study  Intervention(s) Administered  
The study includes a screening  period of up to 28 days, a 7- day interventional period, and a 
28-35 day follow-up period. The duration of study participation for each participant is 
approximately 9-10 weeks. 
 
Study  Intervention(s)  
Intervention  Name  [CONTACT_773360]  (PF-06651600)  
Arm  Name  
(group of participants receiving  a specific 
treatment or no treatment)  Active study medication  
Unit  Dose  Strength(s)  20 mg 
Route of Administration  Oral 
Use Experimental  
IMP or NIMP/AxMP  IMP 
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1061896] 2022  
PFIZER  CONFIDENTIAL  
Page  38  
  
Study  Arm(s)  
Arm  Title Active study medication  
Arm  Type  Active study medication  
Arm Description  Participants  will receive study medication,  20 mg per day, for 7 days.  
Each  site will receive an initial shipment with enough IP for two participants.  Replacements 
will be provided to the study site as the initial supply is used or expi[INVESTIGATOR_5697]. 
6.1.1. Administration  
Ritlecitinib will be provided to the study  sites as capsules.  
For administration,  the capsules will be dissolved in water  and the contents of the capsule in 
water will be taken. No other liquids are allowed (carbonated water, soda, fruit juices). DO 
NOT ADD SUGAR OR ANY SWEETENER.  
The first dose will be administered at the study site, in presence of the investigator or designee,  who will instruct the participant and the parents/legal guardians, in detail,  on how 
the treatment should be taken. 
VERY  IMPORTANT:  
a. The Investigational Product must  be administered  immediately  after preparation  and 
never stored.  
b. The capsule must be dissolved in water  according  to the dosing administration 
instructions.  
c. Treatment  will be administered  in the morning, after breakfast.  
d. Time  of the  administration  will be documented on a daily  basis.  The Investigator  or 
designee will collect this information during the study visits and record in the Case 
Report Form. 
e. If vomiting  occurs within  [ADDRESS_1061897] confirm that appropriate conditions (eg, temperature)  have been  maintained  during transit  for all study  interventions received 
and any discrepancies are reported and resolved  before use of the study intervention.  
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1061898] 2022  
PFIZER  CONFIDENTIAL  
Page  39  
 2. Only  participants enrolled  in the study  may receive study intervention and only 
authorized site staff may  supply, prepare, and/or administer study intervention. 
3. All study interventions must be stored in a secure, environmentally controlled, and 
monitored (manual or automated recording) area in accordance with the labeled storage conditions with access limited to the investigator and authorized site staff. At a minimum, daily  minimum and maximum temperatures for all site storage locations 
must be documented and available upon request. Data for nonworking days must indicate  the minimum  and maximum temperatures  since  previously documented upon 
return to business.  
4. Any excursions from the study intervention label storage conditions should be reported to [COMPANY_007]  upon discovery along with actions taken. The site should actively 
pursue options for returning the study intervention to labeled storage conditions, as soon as possible. Once an excursion is identified, the study intervention must be quarantined and not used until [COMPANY_007] provides permission to use the study intervention. Specific details regarding the excursion definition and information to report for each excursion will be provided to the site in the IP manual.  
5. Any storage conditions stated in the SRSD will be superseded by [CONTACT_773340].  Site staff will instruct  participants  on the proper  storage 
requirements for take home study intervention. See the Investigational Product Manual for storage conditions of the study intervention once reconstituted. 
6. Study interventions should be stored  in their original containers.  
7. The investigator, institution, head of the medical institution (where applicable), or authorized site staff is responsible for study intervention accountability, reconciliation, and record maintenance (ie, receipt, reconciliation, and final disposition records), such as the IPAL or sponsor-approved equivalent. All study interventions will be accounted for using a study intervention accountability form/record. All ritlecitinib that is taken home by [CONTACT_2299], both used (empty capsules)  and unused capsules,  must be returned  to the investigator  by [CONTACT_2299]. 
Returned study intervention must not be re -dispensed to the participants.  
8. Further guidance and information for the final disposition of unused study interventions are provided in the Investigational Product Manual. All destruction must be adequately documented. If destruction is authorized to take place at the investigator site, the investigator must ensure that the materials are destroyed in compliance with applicable environmental regulations, institutional policy, and any 
special instructions provided by [CONTACT_4618]. 
Upon identification  of a product complaint,  notify the sponsor within  1 business day of 
discovery as described in the IPM.  
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1061899] 2022  
PFIZER  CONFIDENTIAL  
Page  40  
 6.2.1. Preparation  and Dispensing  
A qualified staff member will dispense the study intervention in the bottles provided, in 
quantities appropriate according to the SoA. A second staff member will verify the 
dispensing. The participant’s parents/legal guardians will be instructed to maintain the product in the bottle  provided throughout the course of dosing and return  the bottle  to the site 
at the next study visit. The investigational product must be maintained in a locked space, out of reach of children. 
The first dose of ritlecitinib  will be administered  at the study site, mixed  with water  (not 
carbonated).  
Specific preparation and administration  instructions  will be provided in the IPM.  
The participant’s  parents/legal guardians will be instructed  on how to prepare and administer 
the next [ADDRESS_1061900] dose of IP (the 7th dose) will be administered  at the study site, in the presence of the 
investigator or designee. The first PK sample will be drawn before administration, then at 
0.5, 1, [ADDRESS_1061901]  be discarded  and 
another capsule will be used. In the unlikely event that the participant will run out of IP (accidental spi[INVESTIGATOR_17378], bottle lost, etc.) the site must be contact[CONTACT_281341], if possible, replacement IP will be provided.  
All used (empty) capsules must be kept and returned at the EOT  visit,  for drug accountability 
purposes.  
6.3. Assignment  to Study  Intervention  
This is an open -label  study. The investigator’s  knowledge of the treatment  assignment  must 
not influence the decision to enroll a particular participant or affect the order in which participants  are enrolled. Given  the small  number of participants  and the nature  of the study 
(PK, PD) it is very unlikely that the investigator decisions may be affected by [CONTACT_239583]. 
6.4. Blinding  
Not applicable. This is an open- label  study.  
6.5. Study  Intervention  Compliance  
Ritlecitinib  will be dispensed to the participants  for the whole duration of the treatment 
(7 days). The first and last dose will be administered at the study site.  
Doses 2
 through 6 will be taken  at home. 
The investigator or designee will provide detailed  instructions  on how to prepare and 
administer the IP.  
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1061902] 2022  
PFIZER  CONFIDENTIAL  
Page  41  
 VERY  IMPORTANT:  
a. If vomiting occurs within  [ADDRESS_1061903] 
be documented and reported at the following visit. Do not use another capsule on the same 
day. Wait until the next day for the following dose. 
When participants self -administer study intervention(s) at home, compliance with study 
intervention will be assessed at each visit (phone visits on Days 2, 4 and 6, site visit on Day 7). During the phone visits, the investigator or designee will make sure the IP was administered  as directed.  On Day 7, compliance will be assessed  by [CONTACT_773341]  (if any). All compliance data will be recorded in the Case Report  Form.  Deviations 
from the prescribed dosage will be recorded in the Case Report Form and documented as protocol deviations. 
A record  of the number of ritlecitinib  capsules dispensed to and taken  by [CONTACT_773342].  
Intervention  start and stop dates,  including dates for intervention delays and/or dose 
reductions, will also be recorded in the CRF. PK samples will not be collected for under- compliant participants. The site must report the 
reason  for undercompliance (including medication  errors,  if appropriate). The participant will 
complete the safety follow -up as described in the SoA . 
6.5.1. Missed  doses 
Between  Days  2 and 5, if a dose is missed  (not more  than one), treatment can be continued as 
scheduled. The date when the dose was missed and the reason must be reported to the site.  
If more than one dose is missed (consecutively or not), participants become unevaluable for 
PK. Once  a second  dose is missed,  treatment  must  be discontinued and no additional doses of 
IP can be taken. The site must be notified as soon as possible. An EOT visit must be scheduled as soon as possible. During the visit, all study procedures, as outlined in the SoA , 
will be conducted, with the exception of the PK sample collection. 
If the dose on Day [ADDRESS_1061904] dose of IP.  
6.6. Dose Modification  
Dose  modification  is not permitted  during the study.  
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1061905]- of-care 
treatments, as advised by [CONTACT_219875].  
6.8. Treatment  of Overdose  
For this study, any dose of ritlecitinib  greater  than 20 mg per day will be considered  an 
overdose.  
There  is no specific treatment  for an overdose. 
In the event of an overdose: 
The participant or parent/caregiver should contact [CONTACT_773343]: the dose 
taken, the date and time of the day and any symptoms experienced after taking the IP. 
The investigator should:  
1. Contact [CONTACT_185605] 24 hours. 
2. Closely  monitor  the participant for any AEs/SAEs  and laboratory abnormalities  as 
medically appropriate and at least until the next scheduled follow -up. 
3. Document the quantity of the excess dose as well as the duration of the overdose in 
the CRF.  
4. Overdose is reportable to  [COMPANY_007]  Safety  only when  associated with  an SAE.  
Decisions regarding dose interruptions or modifications will be made by [CONTACT_773344].  
6.9. Prior  and Concomitant Therapy  
6.9.1. Prohibited Medications 
Any of the following treatment regimens specified  in the timeframes  outlined below:  
a. At any time: previous use of any non-B- cell selective lymphocyte-depleting agent (eg, 
alefacept, alemtuzumab).  
b. Within  [ADDRESS_1061906] dose of study  intervention  or 5 half- lives  (if known), or until 
lymphocyte count returns  to normal,  whichever is longer: any B- cell-depleting agents, 
including but not limited to rituximab.  
c. W ithin  [ADDRESS_1061907] dose of study intervention  or 5 half-lives  (if known), whichever 
is longer: 
• Any JAK inhibitor for use in any disease indication  (including  topi[INVESTIGATOR_773306])  
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1061908] 2022  
PFIZER  CONFIDENTIAL  
Page  43  
 • Immunomodulatory  biologic agents.  
Note:  Discontinuation  of any JAK inhibitor due to a treatment -related adverse event  is 
exclusionary (see exclusion 9).  
d. Within  [ADDRESS_1061909] dose of study intervention or within  5 half-lives  (if known), 
whichever is longer:  
• Immunosuppressants (eg, cyclosporine A, azathioprine, MTX,  sulfasalazine, 
MMF, everolimus, ibrutinib).  
• Oral or injectable  steroids.  
e. Within  [ADDRESS_1061910] dose of study intervention: vaccination  with attenuated  live 
vaccine.  
f. Within  [ADDRESS_1061911] dose of study  intervention  or 5 half-lives  (if known), whichever 
is longer: prohibited CYP3A inducers as described in Section 6.9.2. 
g. Within [ADDRESS_1061912] dose of study  intervention: 
• Herbal  medications with either unknown properties or pharmaceutical properties 
that impact PK  
• Prohibited CYP3A and CYP1A2  substrates  as described  in Section  6.9.2 (within 
7 days or 5 half-lives, whichever is longer). 
6.9.2. Prohibited and Permitted  Concomitant CYP3A Inducers,  and CYP3A and 
CYP1A2 Substrates  
This is not an all -inclusive list. Study  personnel should stay current and consult with their 
pharmacy to exclude all concomitant medications that are moderate to potent CYP3A 
inducers or sensitive or moderate sensitive CYP3A or CYP1A2 substrates. If a medication is a sensitive or moderate  sensitive CYP3A  or CYP1A2  substrate  and is not listed  below as 
prohibited or permitted, consultation with the Sponsor is required. 
[IP_ADDRESS]. Prohibited Concomitant CYP3A Inducers  and Substrates 
Refer  to Table  3. 
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1061913] 2022  
PFIZER  CONFIDENTIAL  
Page  44  
 [IP_ADDRESS]. Permitted  Concomitant CYP3A Substrates  
 
Sensitive  CYP3A  Substrates ## Moderate  Sensitive  CYP3A 
Substrates § 
Alfentanil  Midazolam  Alprazolam  
Avanafil  Naloxegol  Atorvastatin  
Buspi[INVESTIGATOR_773307]    
## Sensitive CYP3A  substrates are drugs that demonstrate an increase in AUC  of ≥5-fold with strong index inhibitors 
of a given metabolic pathway in clinical DDI studies.  
Topi[INVESTIGATOR_2855] (including skin or mucous  membranes)  application of antimicrobial and antifungal medications  is permitted.  
§ Moderate sensitive  substrates are drugs that demonstrate an increase  in AUC  of ≥2 to <5-fold.  
 
[IP_ADDRESS]. Prohibited Concomitant CYP1A2  Substrates  
Refer  to Table  4. 
[IP_ADDRESS]. Permitted  Concomitant CYP1A2  Substrates  
 
Sensitive  CYP1A2  Substrates  Moderate  Sensitive  CYP1A2  Substrates  
Alosetron 
Duloxetine 
Melatonin 
Ramelteon  
Tasimelteon  Clozapi[INVESTIGATOR_773308] ≥[ADDRESS_1061914]  in clinical  DDI studies. Topi[INVESTIGATOR_2855]  (including  skin or mucous 
membranes) application of antimicrobial and antifungal medications is permitted.  
Moderate  sensitive  substrates  are drugs  that demonstrate  an increase  in AUC  of ≥2 to <5-fold. 
 
7. DISCONTINUATION OF STUDY  INTERVENTION AND  PARTICIPANT 
DISCONTINUATION/WITHDRAWAL  
7.1. Permanent  Discontinuation  of Study  Intervention  
It may be necessary  for a participant to permanently  discontinue study intervention. Reasons 
for permanent discontinuation of study intervention may include the following: Adverse 
Event, Protocol Deviation, Withdrawal of Consent, Pregnancy, and/or COVID-19. 
Note  that discontinuation of study intervention does not represent  withdrawal from the study. 
If study intervention is permanently discontinued, the participant should remain in the study 
to be evaluated for safety [ADDRESS_1061915] dose of IP. See the SoA for data to be 
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1061916] be documented on the 
appropriate CRF/in the medical records whether the participant is discontinuing further receipt  of study intervention  or also from  study procedures, posttreatment  study follow -up, 
and/or future collection of additional information. 
It is recommended  that the investigator discuss temporary  or permanent  discontinuation of 
study intervention with the study medical monitor. 7.1.1. Adverse Event  
Study intervention  must  be permanently  discontinued, and the EOT Visit  completed, if the 
participant experiences:  
• Serious infections  (defined  as any infection  [viral,  bacterial,  and fungal] requiring 
parenteral antimicrobial therapy or hospi[INVESTIGATOR_773309]);  
• Treatment  related  SAEs;  
• Other  serious or severe AEs,  at the  discretion of  the investigator or sponsor.  
All Adverse Events leading  to permanent discontinuation of IP must be documented in the 
CRF indicating action taken with study drug as permanently discontinued. The EOT CRF page must show reason for treatment discontinuation as “Adverse Event”.  
7.1.2. Protocol Deviation  
Study intervention  must  be permanently  discontinued, and the EOT  Visit completed  for 
protocol deviations such as: 
• Use of prohibited medication  
• Not meeting  all eligibility  criteria  (eg, incidental monitoring  findings during phone 
calls)  
• Treatment  under- compliance (missing  more  than one dose of IP between  Day 2 and 5, 
missed dose on Day 6). 
7.1.3. Withdrawal of Consent  
Participants  may withdraw  from the study at any time. If the consent is withdrawn  during the 
treatment period (Days 1 to 7), an EOT visit must be completed. If the withdrawal is complete,  from  all study procedures,  an EOS  visit study must  be conducted at the same  time.  
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1061917] be taken  so the PK analyses can be 
conducted at the end of the treatment. 
Temporary  discontinuations are allowed  only from Day 2 and until Day 5, and only for one 
day. If two or more doses (consecutive or not) are missed between Day [ADDRESS_1061918] 
dose of IP. 
7.2. Participant  Discontinuation/Withdrawal From  the Study  
Participants  may be withdrawn  from the study at any time at the request  of their parents/legal 
guardians.  
If a participant decides to discontinue treatment for any reason,  all efforts  should be made to 
conduct a safety follow-up visit [ADDRESS_1061919] dose of IP. If not possible 
(withdrawal of consent, etc.) an Early  discontinuation visit will be completed. All EOT and 
End of Study procedures will be conducted according to the SoA . At the time of 
discontinuing from the study, if possible, an early  discontinuation visit should be conducted. 
See t
he SoA for assessments to be collected  at the time of study  discontinuation and 
follow -up and for any further evaluations that need to be completed. 
The early  discontinuation visit applies  only to participants  who  are enrolled/randomized  and 
then are prematurely  withdrawn  from the study. Participants  should be questioned regarding 
their reason for withdrawal.  
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1061920] document any such requests in the 
site study records and notify the sponsor accordingly. 
If the participant withdraws  from the study and also withdraws  consent (see Section  7.2.1) 
for disclosure of future information, no further evaluations will be performed and no 
additional data will be collected. The sponsor may retain and continue to use any data collected before such withdrawal of consent. 
7.2.1. Withdrawal of Consent  
Participants who request to discontinue receipt of study  intervention will remain in the study 
and must continue to be followed for protocol- specified follow -up procedures. The only 
exception to this is when a participant specifically withdraws consent/assent for any further 
contact [CONTACT_219879]. Participants  should notify the investigator in writing  of the decision  to withdraw 
consent from future follow -up, whenever possible. The withdrawal of consent should be 
explained  in detail in  the medical records  by [CONTACT_093], as to whether the withdrawal is 
only from further receipt of study intervention or also from study procedures and/or posttreatment study follow-up, and entered on the appropriate CRF page. In the event that 
vital status (whether the participant is alive or dead) is being measured, publicly available 
information should be used to determine vital status only as appropriately directed in accordance with local law.  
7.3. Lost  to Follow -Up 
A participant will be considered  lost to follow -up if the participant repeatedly  fails to return 
for scheduled visits and is unable to be contact[CONTACT_9298]. 
The following actions must  be taken  if a participant fails to return  to the clinic  for a required 
study visit: 
• The site must attempt to contact [CONTACT_14315]. Counsel the participant on the importance of maintaining the assigned  visit schedule, and ascertain  whether the participant wishes to and/or should 
continue in the study; 
• Before a participant is deemed lost to follow -up, the investigator or designee must 
make every  effort to regain  contact [CONTACT_6635]  (where  possible, 3 telephone 
calls and, if necessary, a certified letter to the participant’s last known mailing address or local equivalent methods). These contact [CONTACT_14316]’s medical record;  
• Should the participant  continue to be unreachable,  the participant will be considered 
to have withdrawn from the study. 
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1061921] 2022  
PFIZER  CONFIDENTIAL  
Page  48  
 8. STUDY ASSESSMENTS AND PROCEDURES  
8.1. Administrative  and Baseline  Procedures  
The investigator (or an appropriate delegate at the investigator site) must  obtain a signed  and 
dated ICD before performing any study- specific procedures.  
Study procedures and their timing  are summarized  in the SoA. Protocol waivers  or 
exemptions are not allowed. 
Adherence to the study design requirements,  including those specified  in the SoA, is essential 
and required for study conduct. All screening evaluations must be completed and reviewed to confirm that potential 
participants  meet  all eligibility  criteria.  The investigator  will maintain  a screening  log to 
record  details  of all participants  screened  and to confirm eligibility  or record  reasons for 
screening failure, as applicable.  
Every effort should be made to ensure that protocol- required tests and procedures are 
completed as described. However, it is anticipated that from time to time there may be circumstances outside the control of the investigator that make it unfeasible to perform the test. In these cases, the investigator must take all steps necessary to ensure the safety and well-being of the participant. When a protocol- required test cannot be performed, the 
investigator will document the reason  for the missed  test and any corrective and preventive 
actions that they have taken to ensure that required processes are adhered to as soon as possible. The study team must be informed of these incidents in a timely manner. 
For samples being collected and shipped, detailed collection, processing, storage, and shipment instructions and contact [CONTACT_773345]. 
Psychological assessments will be conducted as described  in the SoA. For additional details, 
refer to Appendix 11 to Appendix 15. 
Severity  of alopecia will also be assessed at screening (SALT) and documented in the CRF.  
The total blood sampling  volume for individual participants  in this study is approximately 
20 ml for the whole study.  
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1061922] Screening  EOT  
Screening  Hematology  0.5 ml 0.5 ml 
Blood  chemistry  0.5 ml 0.5 ml 
QFT 1 ml  
IP-10 1 ml 1 ml 
Lymphocyte  subsets  2 ml 2 ml 
Hepatitis  B and C 2 ml  
HIV 2 ml  
Pregnancy  (serum)  2 ml  
Day 7 PK  5 ml (5 × 1 ml) 
Total  Blood  Sampling  Volume  11 ml 9 ml 
 
Additional blood tests may be required, at the Investigator’s discretion.  
TBV is equal to the participant’s weight in kg multiplied by [CONTACT_773346]/kg (80 -90 
ml/kg  for children). EU and WHO guidelines suggest  that no more  than 1% of TBV should 
be drawn in a 24- hour period and no more that 3% of TBV should be drawn over [ADDRESS_1061923] data points. Telehealth includes the exchange of healthcare information and services via telecommunication technologies (eg, audio, video, videoconferencing software) remotely, allowing the participant  and the investigator to communicate on aspects of clinical  care,  including medical 
advice, reminders, education, and safety monitoring. 
Study Visits  at Days  2, 4 and 6, and the EOS  (Follow-up) visit will be conducted by [CONTACT_648]. 
Study data will be collected as described in the SoA . 
The following assessments must be performed  during a telehealth  visit (see the SoA): 
• Review  and record  study intervention(s),  including compliance  and missed  doses.  
• Review  and record  any AEs and SAEs  since the last contact.  Refer  to Section  8.4. 
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1061924] 2022  
PFIZER  CONFIDENTIAL  
Page  50  
 • Review  and record  any new concomitant medications  or changes in concomitant 
medications since the last contact.  
• Review  and record  contraceptive method and results of pregnancy testing. Confirm 
that the participant is adhering to the contraception method(s) required in the 
protocol. Refer to Appendix 4. 
Study participants  must be reminded  to promptly  notify  site staff about any change in their 
health status.  
8.1.3. Home  Health  Visits  
A home health care service may be utilized to facilitate scheduled visits. Home health visits include a healthcare  provider conducting an in-person  study visit at the participant’s  location, 
rather than an in -person study visit at the site. The following may be performed during a 
home health visit (see the SoA): 
• Review  and record  study intervention(s),  including compliance and missed  doses.  
• Review  and record  any AEs and SAEs  since the last contact.  Refer  to Section  8.4. 
• Review  and record  any new concomitant medications  or changes in concomitant 
medications since the last contact.  
• Review  and record  contraceptive method and results of pregnancy testing. Confirm 
that the participant is adhering to the contraception method(s) required in the protocol. Refer to Appendix 4. 
• On day 7, the last two PK samples ([ADDRESS_1061925] dose) may be collected  at 
home.  
It is recommended  that the investigator discuss temporary  or permanent  discontinuation of 
study intervention with the study medical monitor. 
8.2. Efficacy  Assessments  
This is a PK, PD study. No efficacy  assessments will be performed.  
8.2.1. Rater Qualifications  
Clinical evaluations will be completed  at screening,  for eligibility  purposes, as follows:  
• SALT score  
• T
aste Assessment Questionnaire  
• The C-SSRS suicidal  ideation  and behavior risk assessment  
• CDRS  
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1061926] 2022  
PFIZER  CONFIDENTIAL  
Page  51  
 • WISC -V (Wechsler  Intelligence  Scale for Children - 5th edition) 
The Taste Assessment  questionnaire is a simple  assessment  that can be conducted by [CONTACT_773347]. 
All other assessments require  experienced  personnel, with skills  in interacting  with children. 
For C -SSRS, specific documented training is required. 
Additional details are provided in specific appendices and study manual, for each assessment.  
For C-SSRS  assessments,  only qualified  raters  will be allowed  to evaluate  and/or rate 
participants in this study (see Appendix 11 for details).  
Training material will be provided to each site, as appropriate. The level of experience with 
the target population (or equivalent), specific scale experience (or equivalent), and certification required (if applicable) will be listed and used to determine whether a rater is approved for a given assessment. The rater must become certified to perform selected study assessments before they can participate in the conduct of the study. For specifically defined assessments, rater training and standardization exercises may be conducted, and written documentation will be provided by [CONTACT_22821]’s certification. In return, each site will be provided written documentation outlining each rater’s certification for specific study assessments.  Recertification  may be required  at periodic  intervals  during the study. The raters 
who administer specific study assessments will be documented in a centralized location and all site staff who administer ratings will be verified in the site study documentation during  
the conduct of the study. 
To ensure consistency and reduce variability, each participant should have all assessments 
conducted by [CONTACT_116207].  Every  effort will be made to have all assessments completed by 
[CONTACT_116207].  
8.3. Safety  Assessments  
Planned time  points for  all safety  assessments are  provided in  the SoA . Unscheduled  safety 
measurements may  be obtained at any time during the study  to assess any  perceived safety 
issues.  
8.3.1. Physical  Examinations  
A complete  physical examination  including height and weight will be performed  at Screening 
and include, at a minimum, an assessment of the following: general appearance, skin, lymph nodes cardiovascular, respi[INVESTIGATOR_696], gastrointestinal and neurological and musculoskeletal systems.  
Brief physical exams will be conducted at Baseline and EOT  and Early  Study Termination.  
Severity  of alopecia will also be assessed  at screening  as described  in Appendix 10 – SALT. 
A minimum of 50% scalp hair loss due to AA is required to be eligible for this study.  
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1061927] physical 
examination findings that are identified during the active collection period and meet the definition of an  AE or SAE ( Appendix 3) must be reported according to the processes in 
Section 8.4.[ADDRESS_1061928] vital sign findings that are identified  during the active collection  period and 
meet the definition of an  AE or SAE ( Appendix 3 ) must be reported according to the 
processes in Section 8.4.1 to Section 8.4.3. 
[IP_ADDRESS]. Blood Pressure and Heart  Rate  
BP and HR measurements will be assessed in supi[INVESTIGATOR_103645] a completely automated device and using a pediatric  cuff of the appropriate size. Manual  techniques will be used only 
if an automated device is not available.  
BP and HR measurements should be preceded  by [CONTACT_2669] [ADDRESS_1061929] of a single 
measurement of HR and 3 BP measurements ([ADDRESS_1061930] 1 minute apart).  The average  of the [ADDRESS_1061931] findings are those that are not associated with 
the underlying disease,  unless judged by [CONTACT_773348]'s condition. 
All laboratory tests with values considered clinically significant and abnormal during participation  in the study or within  [ADDRESS_1061932] dose of study intervention  should be 
repeated until the values return to normal or baseline or are no longer considered clinically significant by [CONTACT_219883].  
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1061933] 2022  
PFIZER  CONFIDENTIAL  
Page  53  
 If such values do not return  to normal/baseline within  a period of time judged reasonable by 
[CONTACT_093], the etiology should be identified and the sponsor notified. 
See Appendix [ADDRESS_1061934] abnormalities. [IP_ADDRESS]. Alternative  Facilities  for Clinical Safety  Laboratory Assessment  
Protocol- specified  safety  laboratory  evaluations must be conducted at a Central  Laboratory.  
Alternatively, additional tests required for diagnosis (such as documentation of Serious 
Adverse Event) can be conducted at a local laboratory, in specific circumstances (time constraints, shippi[INVESTIGATOR_773310],  etc.) The local  laboratory  may be a standalone institution 
or within a hospi[INVESTIGATOR_307].  
If a local laboratory is used, qualified study site personnel must order, receive, and review results. Site staff must collect the local laboratory reference ranges and certifications/ accreditations  for filing  at the site. Laboratory  test results are to be provided to the site staff 
as soon as possible.  The local laboratory reports should be filed in the participant’s source 
documents/medical records. Relevant data from the local laboratory report should be recorded  on the CRF.  
8.3.4. Pregnancy  Testing  
All WOCBP  participating  in this study  must have a pregnancy test performed  at Screening, 
Baseline and EOT  visit. Definition of a WOCBP  participant is provided in Section 10.4.3. 
A serum pregnancy test is required at screening. Following screening, pregnancy tests may be urine or serum tests, and must have a sensitivity of at least 25 mIU/mL. Pregnancy tests will be performed  in WOCBP  at the times  listed  in the SoA. Following  a negative pregnancy 
test result at screening,  appropriate contraception must be commenced  and a second  negative 
pregnancy test result will be required at the baseline visit prior to the participant’s receiving the first dose of ritlecitinib. Pregnancy  tests will also be done whenever 1 menstrual cycle is 
missed during the active treatment period (or when potential pregnancy is otherwise suspected) and at the end of the study. Pregnancy tests may also be repeated if requested by [CONTACT_1202]/ECs or if required by [CONTACT_427].  
If a urine test cannot be confirmed  as negative (eg, an ambiguous result),  a serum  pregnancy 
test is required. In such  cases,  the participant must  be excluded if the serum  pregnancy result 
is positive. 
The PI w
ill review  the results  of the pregnancy test as soon as they are available and 
communicate the results to the parents/legal guardians within the next 24 hours. Notification of parents/legal guardians must comply  with local regulations.  
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1061935] 2022  
PFIZER  CONFIDENTIAL  
Page  54  
 8.3.5. Suicidal  Ideation and Behavior Risk  Monitoring  
Suicidal Ideation and Behavior will be assessed at Screening using the C- SSRS (Columbia 
Suicide Severity  Rating  Scale – pediatric  version, baseline assessment)  version  for pediatric 
patients 6 to 11 years old ( Appendix 11).  
Due to the short duration of treatment,  this assessment  will be performed  only at screening, 
for eligibility purposes. The assessment will not be performed at the Follow -up visit 
(28-[ADDRESS_1061936] study intervention administration).  
8.4. Adverse Events,  Serious Adverse Events,  and Other  Safety  Reporting  
The definitions of an AE and an SAE can be found in Appendix 3 . 
AEs may arise from symptoms or other complaints reported to the investigator by [CONTACT_2416] (or, when appropriate, by a caregiver, surrogate, or the participant's legally authorized representative),  or they may arise from  clinical  findings of the investigator or 
other healthcare providers (clinical signs, test results, etc).  
The investigator and any qualified  designees are responsible for detecting, documenting, and 
recording events that meet the definition of an  AE or SAE and remain responsible to pursue 
and obtain adequate information both to determine the outcome and to assess whether the event meets the criteria for classification as an SAE or caused the participant to discontinue the study intervention (see Section 7.1).  
During the active collection period as described in Section 8.4.1, each participant and parent/legal  guardian will be questioned  about the occurrence of AEs in a nonleading manner. 
In addition, the investigator may be requested  by [CONTACT_644735] -up 
information in an expedited fashion. 
8.4.1. Time  Period  and Frequency  for Collecting  AE and SAE  Information  
The time period for actively eliciting and collecting AEs and SAEs (“active collection 
period”) for each participant begins from  the time the participant provides informed  consent, 
which is obtained before undergoing any study- related procedure and/or receiving study 
intervention, through and including a minimum of [ADDRESS_1061937] administration of the study intervention. 
Follow-up by [CONTACT_773349] a level acceptable to the investigator.  
When  a clinically  important  AE remains  ongoing at the end of the active collection  period, 
follow -up by [CONTACT_227985] a level acceptable to the investigator and [COMPANY_007] concurs with that assessment.  
For p
articipants  who are screen  failures,  the active collection  period ends when  screen  failure 
status is determined.  
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1061938] SAE Report Form.  
[IP_ADDRESS]. Reporting  SAEs  to [COMPANY_007] Safety  
All SAEs occurring in a participant during the active collection period as described in Section  8.4.[ADDRESS_1061939] SAE  Report Form  immediately  upon 
awareness and under no circumstance should this exceed 24 hours, as indicated in Appendix 3. The investigator will submit any updated SAE data to the sponsor within 
24 hours of its being available.  
[IP_ADDRESS]. Recording  Nonserious AEs and SAEs  on the CRF  
All nonserious AEs and SAEs occurring in a participant during the active collection period, which  begins after obtaining informed  consent as described  in Section  8.4.1, will be recorded 
on the AE section of the CRF. 
The investigator is to record  on the CRF  all directly  observed and all spontaneously reported 
AEs and SAEs reported by [CONTACT_2299]. 
As part of ongoing safety reviews conducted by [CONTACT_456], any nonserious AE that is 
determined  by [CONTACT_749830].  To assist 
in the determination of case seriousness, further information may be requested from the investigator to provide clarity and understanding of the event in the context of the clinical study.  
8.4.2. Method  of Detecting  AEs and SAEs  
The method of recording,  evaluating, and assessing  causality  of AEs and SAEs  and the 
procedures for completing and transmitting SAE reports are provided in Appendix 3. 
Care  will be taken  not to introduce bias when  detecting AEs and/or SAEs.  Open -ended and 
nonleading verbal questioning of the participant is the preferred method to inquire about AE occurrences.  
8.4.3. Follow- Up of AEs and SAEs  
After the initial AE or SAE report, the investigator is required to proactively follow each participant  at subsequent visits/contacts. For each event, the investigator must pursue and 
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1061940] to follow -up (as defined in Section 7.3).  
In general, follow-up information  will include a description  of the event in sufficient  detail  to 
allow for a complete medical assessment of the case and independent determination of 
possible causality.  Any information relevant to the event, such as concomitant medications 
and illnesses, must be provided. In the case of a participant death, a summary of available autopsy findings must be submitted as soon as possible to [COMPANY_007] Safety. 
Further information  on follow-up procedures is provided in Appendix [ADDRESS_1061941]  the safety  of participants  and the safety  of a 
study intervention under clinical investigation are met.  
The sponsor has a legal responsibility  to notify both the local regulatory  authority  and other 
regulatory  agencies about the safety  of a study intervention  under clinical  investigation.  The 
sponsor will comply with country- specific regulatory requirements relating to safety 
reporting to the regulatory authority, IRBs/ECs, and investigators. 
Investigator safety  reports  must be prepared  for S[LOCATION_003]Rs  according to local  regulatory 
requirements and sponsor policy and forwarded to investigators as necessary. An investigator who receives S[LOCATION_003]Rs or other specific safety information (eg, summary or 
listing  of SAEs)  from the sponsor will review  and then file it along with the SRSD(s)  for the 
study and will notify the IRB/EC, if appropriate according to local requirements. 
8.4.5. Environmental  Exposure,  Exposure  During  Pregnancy  or Breastfeeding,  and 
Occupational Exposure 
Environmental exposure occurs when a person not enrolled in the study as a participant 
receives unplanned direct contact [CONTACT_273478]. Such exposure may or may not lead to the occurrence of an AE or SAE. Persons at risk for environmental exposure include healthcare  providers, family  members,  and others  who may be exposed. An 
environmental exposure may include EDP, EDB, and occupational exposure. 
Any such exposures to the study intervention under study are reportable to [COMPANY_007]  Safety 
within 24 hours of investigator awareness. [IP_ADDRESS]. Exposure During Pregnancy  
Due to the short duration of treatment and age of participants  (6 to 11 years old) EDP  is 
unlikely to occur. 
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1061942] 2022  
PFIZER  CONFIDENTIAL  
Page  57  
 An EDP  occurs if: 
• A female  participant is found to be pregnant while  receiving  or after discontinuing 
study intervention. 
• A male  participant  who is receiving  or has discontinued study intervention 
inseminates a female partner.  
• A female  nonparticipant is found to be pregnant while  being exposed or having been 
exposed to study intervention because of environmental exposure. Below are 
examples of environmental EDP: 
• A female  family  member  or healthcare  provider reports that she is pregnant after 
having been exposed to the study intervention by [CONTACT_78262]. 
• A male  family  member  or healthcare  provider who has been  exposed to the study 
intervention by [CONTACT_219891]. 
The investigator must report EDP  to [COMPANY_007] Safety within 24 hours of the investigator’s 
awareness,  irrespective of whether an SAE  has occurred. The initial information  submitted 
should include the anticipated date of delivery (see below for information related to termination of pregnancy). 
• If EDP occurs in a participant/participant’s partner, the investigator must report this information  to [COMPANY_007]  Safety  on the CT SAE  Report  Form  and an EDP  Supplemental 
Form, regardless of whether an SAE has occurred. Details of the pregnancy will be collected after the start of study intervention and until [ADDRESS_1061943] dose.  
• If EDP  occurs in the setting  of environmental exposure, the investigator must report 
information  to [COMPANY_007]  Safety  using the CT SAE  Report Form  and EDP  Supplemental 
Form. Since the exposure information does not pertain to the participant enrolled in the study, the information is not recorded on a CRF; however, a copy of the completed CT SAE Report Form is maintained in the investigator site file.  
Follow-up is conducted to obtain general information on the pregnancy and its outcome for all EDP  reports with an unknown outcome. The investigator will follow the pregnancy  until 
completion (or until pregnancy termination) and notify [COMPANY_007] Safety of the outcome as a follow -up to the initial EDP Supplemental Form. In the case of a live birth, the structural 
integrity  of the neonate can be assessed  at the time of birth.  In the event of a termination,  the 
reason(s) for termination should be specified and, if clinically possible, the structural integrity of the terminated fetus should be assessed by [CONTACT_4692] (unless 
preprocedure test findings are conclusive for a congenital anomaly and the findings are 
reported).  
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1061944] 2022  
PFIZER  CONFIDENTIAL  
Page  58  
 Abnormal pregnancy outcomes are considered SAEs.  If the outcome of the pregnancy meets 
the criteria for an SAE (ie, ectopic pregnancy, spontaneous abortion, intrauterine fetal 
demise, neonatal death, or congenital anomaly in a live‑born baby, a terminated fetus, an intrauterine fetal demise, or a neonatal death), the investigator should follow the procedures for reporting SAEs.  Additional information about pregnancy outcomes that are reported to 
[COMPANY_007] Safety as SAEs follows:  
• Spontaneous abortion including miscarriage  and missed  abortion  should be reported 
as an SAE;  
• Neonatal  deaths that occur within  [ADDRESS_1061945] 
to causality, as SAEs. In addition, infant deaths after 1 month should be reported as 
SAEs when the investigator assesses the infant death as related or possibly related to 
exposure to the study intervention.  
Additional information regarding the EDP  may be requested by [CONTACT_456]. Further 
follow -up of birth outcomes will be handled on a case-by- case basis (eg, follow -up on 
preterm infants to identify developmental delays). In the case of paternal exposure, the investigator will provide the participant with the Pregnant Partner  Release of Information  
Form to deliver to his partner. The investigator must document in the source documents that the participant was given the Pregnant Partner  Release of Information  Form  to provide to his 
partner.  
[IP_ADDRESS]. Exposure  During  Breastfeeding  
An EDB occurs if:. 
• A female participant is found to be breastfeeding  while  receiving or after 
discontinuing study intervention. 
• A female  nonparticipant is found to be breastfeeding  while  being exposed or having 
been exposed to study intervention (ie, environmental exposure). An example of environmental EDB is a female family member or healthcare provider who reports that she is breastfeeding after having been exposed to the study intervention by [CONTACT_78262].  
The investigator must report EDB to [COMPANY_007] Safety within 24 hours of the investigator’s awareness, irrespective of whether an SAE has occurred. The information must be reported using the CT SAE  Report  Form.  When  EDB  occurs in the setting  of environmental exposure, 
the exposure information does not pertain to the participant enrolled in the study, so the information is not recorded on a CRF. However, a copy of the completed CT SAE Report Form is maintained in the investigator site file.  
An EDB report is not created when a [COMPANY_007] drug specifically approved for use in breastfeeding women (eg, vitamins) is administered in accordance with authorized use. However,  if the infant  experiences an SAE  associated  with such a drug, the SAE  is reported 
together with the EDB. 
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1061946] 2022  
PFIZER  CONFIDENTIAL  
Page  59  
 [IP_ADDRESS]. Occupational Exposure  
The investigator must report any  instance of occupational exposure to [COMPANY_007] Safety within 
24 hours of the investigator’s awareness using the CT SAE Report Form, regardless of 
whether there  is an associated  SAE.  Since the information  about the occupational exposure 
does not pertain to a participant enrolled in the study, the information is not recorded on a CRF; however, a copy of the completed CT SAE Report Form must be maintained in the investigator site file.  
8.4.6. Cardiovascular and Death  Events  
Not applicable.  
8.4.7. Disease Related  Events  and/or  Disease Related  Outcomes  Not Qualifying  as AEs 
or SAEs  
Not applicable.  
8.4.8. Adverse Events  of Special  Interest  
AESIs  for this study include serious or opportunistic infections,  viral reactivation,  decreases 
in lymphocytes or platelets, and dermatologic events, including urticaria and rash. 
AESIs are examined as part of routine safety data review procedures throughout the clinical 
trial and as part of signal detection processes. Should an aggregate analysis indicate that these prespecified  events occur more  frequently  than expected, eg, based  on epi[INVESTIGATOR_227924], literature, or other data, then this will be submitted and reported in accordance with [COMPANY_007]’s safety reporting requirements. Aggregate analyses of safety data will be performed on a regular basis per internal SOP.  
All AESIs must be reported as an AE or SAE following the procedures described in Section  8.4.[ADDRESS_1061947] SAE Report Form.  
[IP_ADDRESS]. Lack  of Efficacy  
Not applicable.  
This is a PK, PD study. The participants  will receive  study treatment  for [ADDRESS_1061948], to ensure a 24 hour interval before the 
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1061949] be reported  as protocol deviation, but 
do not represent medication errors. Medication  errors  are recorded and reported as follows:  
 
Recorded on the 
Medication  Error Page 
of the CRF  Recorded on the 
Adverse Event  Page 
of the CRF  Reported on the CT SAE 
Report Form to [COMPANY_007] 
Safety  Within  24 Hours of 
Awareness  
All (regardless  of whether 
associated with an AE)  Any AE or SAE  associated 
with the medication error Only  if associated  with an 
SAE 
Medication  errors  include:  
• Medication  errors  involving participant exposure to the study intervention; 
• Potential medication  errors  or uses outside of what  is foreseen  in the protocol that do 
or do not involve the study participant. 
• Administration of expi[INVESTIGATOR_336249]  
• Administration  of study intervention  that has undergone temperature  excursions from 
the specified storage range unless it is determine by [CONTACT_240855]. 
Such  medication  errors  occurring to a study participant are to be captured  on the medication 
error page of the CRF, which is a specific version of the AE page. 
Whether or not the medication error is accompanied by [CONTACT_120909], as determined by [CONTACT_1275],  the medication  error is recorded  on the medication  error page  of the CRF  and, if 
applicable, any associated  AE(s), serious and nonserious, are recorded on the AE page of the 
CRF.  
In the event  of a medication  dosing error,  the sponsor should be notified  within  [ADDRESS_1061950] SAE  Report 
Form only when associated with an SAE.  
8.5. Pharmacokinetics  
Blood samples to provide  plasma for PK analysis  will be collected  into appropriately  labeled 
tubes containing K2EDTA anticoagulant at times specified in the SoA section of the  
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1061951] sample  
([ADDRESS_1061952] dose) and the last two samples ([ADDRESS_1061953] dose) can be collected  at 
home.  
If a peripheral venous catheter  was installed  for collection  of the first [ADDRESS_1061954] dose, will be 
collected by [CONTACT_773350].  
Blood will be collected at the time points identified in the SoA section of the protocol. On 
the PK sampling visit (Day 7), participants will be asked about the dosing time on the day before the visits and the investigational site personnel will record it in the data collection tool (eg, CRF).  Participants  will be instructed  to not take their daily  dose at home on the PK 
sampling day, but to bring the dose to the investigational site for the PK sampling visit and they will be instructed at the site when to take their dose. The IP should be administered in 
the morning, at breakfast, to allow completion of the PK collection (8 hours) within site 
working hours. All efforts will be made to obtain the PK samples at the exact nominal time relative to dosing. For each blood sample collection, the allowable windows are as follows for times post dose: 0.5 hr (±10 min), 1 hr (±15 min), 3 hr (±20 min) and 8 hr (±30 min). 
The date and exact time of dosing and the sample collection will be entered into source document and data collection  tool (eg, CRF),  as well as the date and time of the previous 
dose (one day prior to the PK sampling day). Samples obtained outside the windows specified in the SoA will be considered a protocol deviation. 
• The plasma will be stored  in appropriately  labeled  screw -capped  polypropylene 
tubes at approximately -20°C or colder within 1 hour of collection. 
• Further details  regarding  the collection,  processing, storage and shippi[INVESTIGATOR_773311]. 
• Samples will be analyzed  using a validated analytical  method in compliance with 
[COMPANY_007] standard operating procedures.  
• The PK samples must be processed and shipped as indicated to maintain sample integrity.  Any deviations from the PK processing  steps,  including any actions taken, 
must be documented and reported to the sponsor. On a case-by- case basis, the 
sponsor may make a determination as to whether sample integrity has been compromised.  Any sample deemed outside of established stability, or of 
questionable integrity, will be considered a  protocol deviation. 
• As pa
rt of understanding the pharmacokinetics of the IP, samples may be used for 
metabolite identification and/or evaluation of the bioanalytical method.  These 
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1061955] nominal time relative to 
dosing. Please consult the laboratory manual(s) for final instructions on sample collection, storage,  and shippi[INVESTIGATOR_29356].  These manual(s)  supersede the instructions  listed  in the 
applicable protocol sections. Samples that are handled according to the respective manual guidance are considered “per protocol”. 
Samples will be analyzed  using fit for purpose or validated  analytical  methods in compliance 
with [COMPANY_007] standard operating procedures.  
As part of understanding the pharmacodynamics of the study drug and the disease under 
study, samples may be used for evaluation  of the bioanalytical method. These data will be 
used for internal (ie, [COMPANY_007]) exploratory purposes and may not be included in the clinical report.  
8.7.1. Biomarkers  
Biomarkers  are not evaluated  in this study.  
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1061956] 2022  
PFIZER  CONFIDENTIAL  
Page  63  
 8.7.2. Samples  for Interferon  Gamma -Induced  Protein  10 (IP-10) Analysis  
Blood samples to provide serum  for the analysis of IP-10 will be collected  into appropriately 
labeled tubes according to the times outlined in the SoA . IP-10 samples will be collected 
from all participants unless the exportation of these samples from the country of origin is 
prohibited by [CONTACT_773351]/EC decision.  
8.7.3. Samples  for Fluorescence-Activated Cell Sorting  Analysis (T Cell,  B Cell,  and NK 
Cell Subsets)  
Blood samples for the assessment of percent and absolute lymphocyte subsets will be collected  and will be analyzed by [CONTACT_773352]  T cell,  B cell,  and NK cell  subsets 
according to the times outlined in the SoA . 
8.7.4. Specified  Gene  Expression  (RNA)  Research  
Specified gene expression (RNA) research is not included in this study.  
8.7.5. Specified  Protein  Research  
Specified  protein research  is not included  in this study.  
8.7.6. Specified  Metabolomic Research  
Specified  metabolomic  research  is not included in this study.  
8.7.7. Retained  Research  Samples  for Biomarkers  
Not applicable.  
8.8. Immunogenicity  Assessments  
Immunogenicity  assessments are not included in this study.  
8.9. Health  Economics  
Health  economics/medical resource utilization  and health  economics parameters  are not 
evaluated in this study. 
9. STATISTICAL CONSIDERATIONS  
Detailed  methodology for summary  and statistical  analyses of the data collected  in this study 
is outlined here and further detailed in the SAP, which will be maintained by [CONTACT_456]. 
The SAP may modify  what  is outlined in the protocol where  appropriate; however, any major 
modifications of the primary endpoint definitions or their analyses will also be reflected in a protocol amendment. 
9.1. Statistical Hypothesis  
No statistical  hypothesis will be tested  in this study.  
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1061957] 2022  
PFIZER  CONFIDENTIAL  
Page  64  
 9.2. Analysis Sets 
For purposes of analysis, the following analysis sets are defined:  
 
Population  Description  
PK Concentration  The PK concentration  population  is defined  as all participants 
treated who have at least [ADDRESS_1061958] they actually received.  
 
9.3. Statistical Analyses  
The SAP will be developed and finalized before any analyses are performed and will 
describe the analyses and procedures for accounting for missing, unused, and spurious data. 
This section is a summary of the planned statistical analyses of the primary and secondary 
endpoints.  
9.3.1. Safety Analyses  
Vital signs, AEs and safety  laboratory  data will be reviewed  and summarized  on an ongoing 
basis during the study to evaluate the safety of participants. Safety data will be presented in 
tabular and/or graphical format and summarized descriptively, where appropriate.  
9.3.2. Pharmacokinetic  Analyses 
PK parameters will be derived  from the concentration time profiles  using noncompartmental 
methods as data permit.  The various PK parameters to be assessed in this study, their 
definition, and method of determination are outlined in Table [ADDRESS_1061959] 
occurrence  
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1061960] 2022  
PFIZER  CONFIDENTIAL  
Page  65  
  
Table 1. Definitions  of PK Parameters 
 
Parameter  Definition  Method  of Determination  
t½ Terminal  elimination  half-life Log e(2)/k el 
Only  those  data points  judged  to describe  the 
terminal  log-linear  decline  will be used in the 
regression.  
CL/F  Apparent  clearance  after oral dose Dose/AUC 24 after oral dose 
VZ/F Apparent  volume  of distribution  after oral 
dose Dose/(AUC 24*kel) after oral dose 
• The plasma PK parameters in Table 1 will be summarized descriptively, as 
applicable, in accordance with [COMPANY_007] data standards.  Individual participant and 
median  profiles  of the plasma concentration- time data will be plotted  using actual  and 
nominal times, respectively. Median profiles will be presented on both linear- linear 
and log- linear scales. Plasma concentrations will be listed and summarized 
descriptively by [CONTACT_458097]. 
9.3.3. Pharmacodynamic Analyses  
All of the PD endpoints will be summarized  by [CONTACT_773353]. 
9.3.4. Taste Assessment Analyses  
Taste acceptability  data will be listed  and summarized  descriptively  (frequencies  and 
percentages).  
9.4. Interim  Analyses  
No formal interim analysis will be conducted for this study.  However, as this is an open - 
label  study, the sponsor may conduct unblinded reviews of the data during the course of the 
study for the purpose of safety assessment, facilitating PK modeling for pediatric dose 
decisions and/or supporting clinical development. 
9.5. Sample Size Determination  
A sample size of 12 participants  was selected  based  on practical  considerations and should 
provide adequate PK information.37,38 
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1061961] 2022  
PFIZER  CONFIDENTIAL  
Page  66  
 10. SUPPORTING  DOCUMENTATION AND OPERATIONAL CONSIDERATIONS  
10.1. Appendix  1: Regulatory, Ethical, and Study Oversight Considerations  
10.1.1. Regulatory and Ethical Considerations  
This study will be conducted in accordance with  the protocol and with the following: 
• Consensus ethical  principles derived from international guidelines, including  the 
Declaration of Helsinki and CIOMS International Ethical Guidelines;  
• Applicable ICH GCP  guidelines;  
• Applicable laws and  regulations, including applicable privacy  laws.  
The protocol, protocol amendments, ICD, SRSD(s), and other relevant documents (eg, 
advertisements)  must be reviewed  and approved by [CONTACT_456], submitted  to an IRB/EC by 
[CONTACT_093], and reviewed and approved by [CONTACT_1201]/EC before the study is initiated. 
Any amendments to the protocol will require IRB/EC approval before implementation of 
changes made  to the study design, except  for changes necessary  to eliminate  an immediate 
hazard to study participants. 
Protocols and any substantial amendments to the protocol will require health authority 
approval prior  to initiation  except  for changes necessary  to eliminate  an immediate  hazard  to 
study participants. 
The investigator will be responsible for the following:  
• Providing written  summaries of the status of the study to the IRB/EC annually or 
more frequently in accordance with the requirements, policies, and procedures 
established by [CONTACT_1201]/EC;  
• Notifying  the IRB/EC of SAEs  or other significant  safety  findings as required  by 
[CONTACT_1744]/EC procedures; 
• Providing oversight of the conduct of the study at the site and adherence to requirements of 21 CFR,  ICH GCP  guidelines, the IRB/EC,  European regulation 
536/2014 for clinical  studies,  European Medical  Device Regulation 2017/745 for 
clinical device research, and all other applicable local regulations.  
[IP_ADDRESS]. Reporting  of Safety  Issues and Serious  Breaches of the Protocol or ICH  GCP  
In the event of any prohibition or restriction  imposed  (ie, clinical  hold) by [CONTACT_22844], or if the investigator is aware of any new information that might influence the evaluation of the benefits and risks of the study intervention, [COMPANY_007] should be informed immediately. 
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1061962], and 
of any serious breaches of this protocol or of the ICH GCP guidelines that the investigator becomes aware of.  
10.1.2. Financial Disclosure  
Investigators and sub- investigators will provide the sponsor with sufficient, accurate 
financial information  as requested  to allow  the sponsor to submit complete  and accurate 
financial certification or disclosure statements to the appropriate regulatory authorities. Investigators are responsible for providing information on financial interests during the course of the study and for 1 year after completion of the study. 
10.1.3. Informed  Consent/Assent  Process  
The investigator or their representative will explain the nature of the study to the participant  and their parent(s)/legal  guardian and answer  all questions regarding  the 
study. The participant  and their parent(s)/legal  guardian should be given  sufficient time and 
opportunity to ask questions and to decide whether or not to participate in the trial. 
When consent is obtained from a participant’s parent(s)/legal guardian, the participant’s 
assent (affirmative agreement) must be subsequently obtained when the participant has the capacity  to provide assent,  as determined  by [CONTACT_1201]/EC. If  the investigator determines  that a 
participant’s decisional capacity is so limited they cannot reasonably be consulted, then, as permitted by [CONTACT_1201]/EC and consistent with local regulatory and legal requirements, the participant’s assent may be waived with source documentation of the reason assent was not obtained. If the study participant does not provide their own assent, the source documents must record why the participant did not provide assent (for example, the child is not of assenting age per local regulations or policies), how the investigator determined that the person signing the consent was the participant’s  parent(s)/legal  guardian, the consent signer’s 
relationship to the study participant, and that the participant’s assent was obtained or  
waived. If assent  is obtained verbally, it must be documented in the source documents. 
If study participants  are minors  who reach  the age of majority  or if a child  reaches the age of 
assent (per local IRB/EC requirements) during the study, as recognized under local law, the child or adolescent must then provide the appropriate assent or consent to document their willingness to continue in the study. For an adolescent who reaches the age of consent, parental consent would no longer be valid. If the enrollment of emancipated minors is permitted by [CONTACT_1201]/EC and local law, the participant must provide documentation of legal 
status to give consent without the permission of a legally authorized representative. 
Participants and their parent(s)/legal guardian must be informed that their participation is 
voluntary. The Participant’s  parent(s)/legal  guardian will be required to sign a statement  of 
informed consent that meets the requirements of 21 CFR 50, local regulations, ICH guidelines, HIPAA requirements, where applicable, and the IRB/EC or study center. 
The investigator must  ensure that each study participant’s  parent(s)/legal  guardian and the 
study participant as applicable are fully informed about the nature and objectives of the  
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1061963] 2022  
PFIZER  CONFIDENTIAL  
Page  68  
 study, the sharing of data related to the study, and possible risks associated with 
participation,  including the risks  associated  with the processing  of the participant’s  personal 
data. 
The participant’s  parent(s)/legal  guardian must  be informed  that the participant’s  personal 
study- related data will be used by [CONTACT_404256]. The level of disclosure must also be explained to the participant’s parent(s)/legal guardian.  
The participant’s  parent(s)/legal  guardian must  be informed  that the participant’s  medical 
records may be examined by [CONTACT_340764], by [CONTACT_6667]/EC members, and by [CONTACT_6668]. 
The investigator further must ensure that each study  participant’s  parent(s)/legal guardian is 
fully informed about their right to access and correct their child’s personal data and to 
withdraw consent for the processing of their child’s personal data, keepi[INVESTIGATOR_770392]’ medical records by [CONTACT_29382](s)/legal guardian in certain regions.  
The source documentation must include a statement that written informed consent and as applicable, assent,  was obtained before  the participant was enrolled  in the study and the date 
the written consent/assent was obtained. The authorized person obtaining the informed consent must also sign the ICD. 
Parent(s)/legal  guardian and the participant must  be reconsented  to the most current  version 
of the ICD(s)/assent during their participation in the study. 
A copy of the ICD(s)  and assent,  if written,  must  be provided to the parent(s)/legal 
guardian and the participant. A participant  who is rescreened  is not required  to sign another ICD if the rescreening  occurs 
within 90 days from the previous ICD signature [CONTACT_568].  
10.1.4. Data  Protection  
All parties will comply with all applicable laws,  including laws regarding  the implementation 
of organizational and technical measures to ensure protection of participant data. Participants’  personal data will be stored  at the study  site in encrypted  electronic  and/or paper 
form and will be password protected or secured in a locked room to ensure that only 
authorized study staff have access. The study site will implement appropriate technical and organizational measures to ensure that the personal data can be recovered in the event of disaster. In the event of a potential personal data breach, the study  site will be responsible for 
determining whether a personal data breach has in fact occurred and, if so, providing breach notifications as required by [CONTACT_2371]. 
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1061964] to the processing of personal 
data, participants will be assigned a single, participant specific numerical code. Any participant  records or data sets that are transferred  to the sponsor will contain the numerical 
code; participant names will not be transferred.  All other identifiable data transferred to the 
sponsor will be identified by [CONTACT_20007], participant- specific code. The study site will 
maintain a confidential list of participants who participated in the study, linking each participant’s numerical code to their actual identity and medical record ID. In case of data transfer,  the sponsor will protect the confidentiality  of participants’  personal  data consistent 
with the clinical study agreement and applicable privacy laws.  
Information  technology systems used to collect,  process,  and store  study- related  data are 
secured by [CONTACT_336272], alteration, or unauthorized disclosure or access. 
The sponsor maintains  standard operating procedures on how to respond in the event of 
unauthorized access, use, or disclosure of sponsor information or systems. 
10.1.5. Committees  Structure  
[IP_ADDRESS]. Data  Monitoring  Committee  
This study will use an E -DMC. The E -DMC is independent of the study team and includes 
only external  members.  The /E-DMC charter  describes  the role of the E- DMC in more  detail.  
The E-DMC will be responsible for ongoing monitoring of the safety of participants in the 
study according  to the charter.  The recommendations made by [CONTACT_941] E- DMC will be forwarded 
to the appropriate authorized [COMPANY_007] personnel for review and final decision. [COMPANY_007] will 
communicate such decisions, which may include summaries of aggregate analyses of endpoint events and of safety data that are not endpoints, to regulatory authorities and investigators, as appropriate. 
10.1.6. Dissemination of Clinical Study Data  
[COMPANY_007] fulfills its commitment to publicly disclose clinical study results through posting the 
results of studies on www.clinicaltrials.gov  (ClinicalTrials.gov), the EudraCT/CTIS, and/or 
www.pfizer.com, and other public registries  and websites in accordance with applicable local 
laws/regulations. In addition, [COMPANY_007] reports study results outside of the requirements of local 
laws/regulations pursuant to its SOPs.  
In all cases, study results are reported by [CONTACT_4715], accurate, balanced, and complete  manner and are reported regardless  of the outcome of the study or the country in 
which the study was conducted. 
www.clinicaltrials.gov  
[COMPANY_007]  posts  clinical  trial results on www.clinicaltrials.gov  for [COMPANY_007]  
sponsored- interventional studies (conducted in patients) that evaluate the safety and/or 
efficacy  of a product, regardless of the geographical location  in which  the study is conducted. 
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1061965]/CTIS  
[COMPANY_007]  posts clinical  trial results on EudraCT/CTIS for [COMPANY_007]  sponsored- interventional 
studies in accordance with the format and timelines set forth by [CONTACT_20009].  
www.pfizer.com  
[COMPANY_007]  posts CSR synopses and plain -language study  results summaries  on www.pfizer.com  
for [COMPANY_007] -sponsored interventional studies at the same time the corresponding study results 
are posted to www.clinicaltrials.gov.  CSR synopses will have personally identifiable 
information anonymized. 
Documents w ithin marketing  applications  
[COMPANY_007]  complies  with applicable local  laws/regulations  to publish clinical documents included 
in marketing applications. Clinical documents include summary documents and CSRs 
including the protocol and protocol amendments, sample CRFs, and SAPs. Clinical documents will have personally identifiable information anonymized. 
Data sharing  
[COMPANY_007] provides researchers secure access to participant level data or full CSRs for the purposes of “bonafide scientific  research” that contributes  to the scientific  understanding of 
the disease, target, or compound class. [COMPANY_007] will make data from these trials available  
[ADDRESS_1061966], including individuals requesting access for commercial/competitive or legal purposes.  
10.1.7. Data Quality Assurance  
All participant data relating  to the study will be recorded  on printed  or electronic  CRF  unless 
transmitted  to the sponsor or designee electronically  (eg, laboratory  data).  The investigator is 
responsible for verifying that data entries are accurate and correct by [CONTACT_1189]. 
Guidance on completion of CRFs  will be provided in the CRF  Completion Requirements 
document.  
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1061967]  ensure that the CRFs  are securely  stored  at the study site in encrypted 
electronic and/or paper form and are password protected or secured in a locked room to 
prevent access by [CONTACT_20011].  
The investigator must permit study related  monitoring, audits,  IRB/EC review,  and regulatory 
agency  inspections and provide direct  access to source data documents. This verification  may 
also occur after study completion. It is important that the investigator(s) and their relevant personnel are available during the monitoring visits and possible audits or inspections and that sufficient time is devoted to the process.  
Monitoring details describing strategy,  including definition  of study- critical  data items  and 
processes (eg, risk-based  initiatives  in operations and quality  such as risk management and 
mitigation strategies and analytical risk -based monitoring), methods, responsibilities, and 
requirements, including handling of noncompliance issues and monitoring techniques (central, virtual, or on-site monitoring), are provided in the data management plan and monitoring plan maintained and utilized by [CONTACT_36613]. 
The sponsor or designee is responsible for the data management  of this study, including 
quality checking of the data. Records and documents, including signed ICDs, pertaining to the conduct of this study must 
be retained by [CONTACT_1732] [ADDRESS_1061968] ensure that the records continue to be stored  securely  for as long as they are 
maintained.  
When  participant data are to be deleted, the investigator will ensure that all copi[INVESTIGATOR_306891].  
The investigator(s) will notify the sponsor or its agents immediately of any regulatory inspection notification in relation to the study. Furthermore, the investigator will cooperate with the sponsor or its agents to prepare the investigator site for the inspection  and will allow 
the sponsor or its agent, whenever feasible, to be present during the inspection. The investigator site and investigator will promptly resolve any discrepancies that are identified between the study data and the participant’s medical records.  The investigator will promptly 
provide copi[INVESTIGATOR_19946]. Before response submission to the regulatory authorities, the investigator will provide the sponsor or its agents with an opportunity to review and comment on responses to any such findings. 
10.1.8. Source Documents  
Source documents provide evidence for the existence of the participant  and substantiate the 
integrity of the data collected. Source documents are filed at the investigator site.  
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1061969] maintain  accurate  documentation (source data)  that supports the 
information entered in the CRF. The sponsor or designee will perform  monitoring to confirm that data entered  into the CRF 
by [CONTACT_1191],  complete,  and verifiable  from source documents; 
that the safety and rights of participants are being protected; and that the study is being 
conducted in accordance with the currently approved protocol and any other study agreements, ICH GCP guidelines, and all applicable regulatory requirements.  
10.1.9. Study and Site Start and Closure  
The study start date is the date on which  the clinical  study will be open for recruitment of 
participants.  
The first act of recruitment is the date of the first participant’s  first visit and will be the study 
start date.  
The sponsor designee reserves the right to close the study site or terminate  the study at any 
time for any reason at the sole discretion of the sponsor, including (but not limited to) regulatory authority decision, change in opi[INVESTIGATOR_1100]/EC, or change in benefit- risk 
assessment. Study sites will be closed upon study completion. A study site is considered closed when all required documents and study supplies have been collected and a study site- closure visit has been performed.  
The investigator may initiate study -site closure at any time upon notification to the CRO if 
requested  to do so by [CONTACT_22846]/EC or if such termination  is required  to protect the 
health of study participants.  
Reasons for the early  closure  of a study  site by [CONTACT_19711]: 
• F
ailure  of the investigator to comply  with the protocol, the requirements  of the 
IRB/EC or local health authorities, the sponsor’s procedures, or the ICH GCP guidelines;  
• Inadequate recruitment of participants by  [CONTACT_093]; 
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1061970] 2022  
PFIZER  CONFIDENTIAL  
Page  73  
 • Discontinuation of further study intervention development.  
If the study is prematurely terminated or suspended, the sponsor shall promptly inform the 
investigators,  the ECs/IRBs,  the regulatory authorities,  and any CRO(s)  used in the study  of 
the reason for termination or suspension, as specified by [CONTACT_1214]. The investigator shall promptly inform the participant and should assure appropriate participant therapy and/or follow- up. 
Study termination  is also provided for in the clinical  study agreement.  If there  is any conflict 
between the contract and this protocol, the contract will control as to termination rights.  
10.1.10. Sponsor’s Medically Qualified Individual  
The contact [CONTACT_1133]’s MQI for the study is documented in the study contact [CONTACT_749803]/study portal or other electronic 
system.  
To facilitate access to their investigator and the sponsor’s MQI for study related - medical 
questions or problems from non- study healthcare professionals, participants are provided 
with an ECC  at the time of informed  consent. The ECC  contains, at a minimum,  (a) protocol 
and study intervention identifiers, (b) participant’s study identification number, (c) site emergency phone number active 24 hours/day, [ADDRESS_1061971], the established communication pathways between  the participant  and their investigator and site staff,  and between  the investigator and 
sponsor study team. The ECC is only to be used by [CONTACT_773354], as a means of reaching the investigator or site staff related  to the care of a 
participant.  
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1061972] 2022  
PFIZER  CONFIDENTIAL  
Page  74  
 10.2. Appendix  2: Clinical Laboratory Tests  
The following safety  laboratory  tests will be performed  at times  defined in the SoA section  of 
this protocol. Additional laboratory results may be reported on these samples as a result of 
the method of analysis or the type of analyzer used by [CONTACT_20019], or as derived from calculated values. These additional tests would not require additional collection of blood. Unscheduled clinical  laboratory  measurements may be obtained at any time during the 
study to assess any perceived safety issues.  
 
Table 2. Protocol- Required  Safety  Laboratory Assessments  
 
Hematology  Chemistry  Urinalysis  Other  
Hemoglobin 
Hematocrit RBC count 
Platelet  count 
WBC count 
Total neutrophils 
(Abs)  
Eosinophils  (Abs) 
Monocytes (Abs) Basophils (Abs) 
Lymphocytes 
(Abs)  Urea  and creatinine 
eCrCl  
Glucose  (fasting) 
Sodium Potassium Chloride  
AST, ALT 
Total bilirubin Alkaline  phosphatase  
Albumin 
Total  protein  Local  dipstick:  
pH 
Glucose (qual) 
P
rotein (qual) 
Albuminuria  (qual) 
Blood (qual) Ketones  
Nitrites  
Leukocyte  esterase  At screening:  
Serum  Pregnancy  test 
(β-hCG)  
IP-10 
QFT 
HIV 
Hepatitis B and C A
t Day 1 and Day 7: 
Urine  pregnancy  test 
 
The investigator must review  the laboratory  report,  document  this review,  and record  any 
clinically relevant changes occurring during the study in the AE section of the CRF. 
Ritlecitinib (PF-0665 1600) 
Protocol B7981031 
 Final Protocol, [ADDRESS_1061973] 2022   
PFIZER  CONFIDENTIAL  
Page  75  
 10.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording , 
Evaluating , Follow- Up, and Reporting  
10.3.1.  Definition of AE 
 
AE Definition  
•  An AE i s any untoward medical occunence in a patient or clini cal study 
paiiicipant, temporally associat ed with the use of study intervention, whether or not 
considered related to the study intervention. 
 
• Note: An AE c an therefore be any unfavo rable and unintende d sign (includin g an 
abno1mal laborato 1y findin g), symptom, or disease ( new o r exacerbat ed) 
temporally associat ed with the use of s tudy intervention. 
 
 
Events Meeting the AE Definition  
•  Any abno1mal  laborato1y test results (hematology, clinical chemistiy, or urinalysis) 
or other safety assessm ents (eg , ECG, radiological scans, vital sign measurements), 
including t hose that worse n from baseline, considered clinically s ignificant in the 
medical and scientific judgment of the investigator. An y abno1mal  laborato 1y test 
result s that meet any of the conditions below must be recorded as  an AE: 
 
• Is associ ated with accompan ying symptoms. 
 
• Requires  additional diagnost ic testing or medical /surgical intervention. 
 
•  Leads to a change  in study dosing (outside of any protocol-specifie d dose 
adjustments) or discontinu ation from the study, signific ant add itional 
concomitant diu g tl'eatment, or other therapy. 
•  Exacerbatio n of a chronic or intennittent preexist ing condition, inclu ding an 
increase in either freq uency and/or intensity of t he condition.  
• New condition detected or diagnosed a fter study intervention adininis tration, even 
though it may have been present before the staii of the study. 
 
• Signs , symptoms, or the clinical sequelae of a suspected diug-di·ug interaction. 
 
•  Signs, symptoms, or the clinical sequelae of a s uspect ed ove rdose of e ither study 
intervention or a concomitan t medication. Overdose  per se will not be repo1ied as 
an AE o r SAE unl ess it is an intentional overdose  taken with possible suicidaVsel f- 
h
aimin g intent. Such overdoses s hould be repo1 ied regardless of  sequelae. 
Ritlecitinib (PF-0665 1600) 
Protocol B7981031 
 Final Protocol, [ADDRESS_1061974] 2022   
PFIZER  CONFIDENTIAL  
Page  76  
  
 
 
Events  NOT Meeting  the AE Definition  
•  Any clinically significant abnonnal laborato 1y findings or other abnonnal safety 
assess ments that are associated  with the underlying disease,  unless judged by [CONTACT_192682] r to be  more sever e than expected for the paiiic ipant's condition. 
 
•  The disease/ disorder be ing studied or expected  progression, signs, or symptoms of 
the disease/ disorder be ing studied, unless more severe than expected for th e 
paiiicipant 's condition. 
 
•  Med ical or surgical p rocedure (eg, endoscopy,  appendecto my): the condition that 
leads to the proced ure is the AE.  
•  Situat ions in which an untowai ·d medical occu nence did not occur (social and/or 
convenience admissio n to a hospi[INVESTIGATOR_307]). 
 
•  Anticipated  day-to-day fluctuatio ns of preexisting  disease(s)  or conditio n(s) present 
or detected at the sta1i of th e study that do not worse n. 
10.3.2. Definition  of an SAE  
 
An SAE  is defined a s any untoward medical  occurrence that , at an y dose, meet s one 
or more of the criteria li sted below:  
a. Results in death  
b. Is life-threatening  
The te1m "life-threaten ing" in the definition of "serious" refers to an even t in which the 
paiiicipant  was at risk of death at the time of the eve nt. It does  not refer to an even t that 
hypotheticall y might have caused death if it were more sever e. 
c.  Require s inpatient  hospi[INVESTIGATOR_773312], hospi[INVESTIGATOR_209417] h as been admitted (usually 
involving at least  an overnight stay)  at the hospi[INVESTIGATOR_773313]/or treatment that wo uld not  have been appropr iate in the physician's office o r 
outpat ient setting. Com plicati ons that occur during hospi[INVESTIGATOR_714779] n ai·e AEs.  If a 
complicatio n prolongs  hospi[INVESTIGATOR_773314] s any other serious criteria, the event  is 
serious. Whe n in doubt  as to whether "hospi[INVESTIGATOR_28689]" occmT ed or was necessaiy, the 
AE s hould be co nsidered ser ious. 
Hospi[INVESTIGATOR_773315] a preexisting cond ition that did not worse n 
from base line is not considered an AE. 
Ritlecitinib (PF-0665 1600) 
Protocol B7981031 
 Final Protocol, [ADDRESS_1061975] 2022   
PFIZER  CONFIDENTIAL  
Page  77  
  
d. Results in persistent  or significant disability /incapacity  
• The te1m disability  means a substantial dismptio n of a person's ability  to conduct 
n01mal life functions. 
•  This definition is not intended to include expe riences of relatively minor medical 
signific ance, such as unco mplicated headache, nausea, vomi ting, dianhea,  
influ enza, and accidental trauma (eg, sprained ankle), that may interfere with or 
prevent eve 1yday life functions but do not con stitute a substantial dismpti on. 
e.  Is a congenital anomaly/birth defect  
f.  Is a suspected  transmis sion via a [COMPANY_007] product of an infectious agent , pathogenic 
or nonpathogenic  
The even t may be suspected from clinical symptoms or laborato 1y findings indicatin g 
an infe ction in a paii icipant exposed  to a [COMPANY_007] p roduct. The te1ms "suspect ed 
transmission" and "transmission" ai·e considered syno nymous. These cases ai·e 
considered unex pected and ha ndled as serio us expedited cases by [CONTACT_773355]. Such cases  ai·e also considered for repo1iing as pro duct defec ts, if 
appropriate. 
g. Other  situation s: 
• Medical or scientific judgme nt should be exercised by [CONTACT_770464]1iin g is appropriate in other situations, such as significan t 
medical event s that may jeopardize the pa1ii cipant or may require medical or 
surgical intervention to prevent one of the other outcomes listed in the above 
definition. These event s should usually be considered serious. 
 
•  Examples of such even ts include invasive  or malignant cancer s, intensive treatm ent 
in an emergency roo m or at home for allergic bro nchospas m, blood dyscras ias or 
convulsions that do not result in hospi[INVESTIGATOR_059], or deve lopment of dmg 
dependency or diu g abu se. 
 
10.3.3.  Recording/Reporting and Follow- Up of AEs  and/or SAEs  During the Active 
Collection Period  
 
AE and SAE Recording/Reporting  
The tab le below s ummari zes the requirements for recording AEs  on the CRF and for 
repo1iing SAEs  on the CT SAE  Repo1i Fo1m to [COMPANY_007] Safety throughout the active 
collection period. These requirements are delin eated for 3 types  of even ts: (1) SAEs; (2) 
nonserious AEs;  and (3) exposure to the study intervention under study during pregnancy 
or breastfee ding, and occ upational exposure. 
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
PFIZER  CONFIDENTIAL  
Page  [ADDRESS_1061976] SAE Report Form for reporting of SAE information.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* EDP  (with  or without an associated  AE or SAE):  any pregnancy information  is reported  to [COMPANY_007] 
Safety  using  the CT SAE  Report Form  and EDP  Supplemental Form;  if the EDP is associated  with an 
SAE, then the SAE is reported to [COMPANY_007] Safety using the CT SAE Report Form.  
** EDB  is reported  to [COMPANY_007]  Safety  using  the CT SAE  Report  Form,  which  would  also include  details 
of any SAE that might be associated with the EDB.  
*** Environmental  or occupational  exposure:  AEs or SAEs  associated  with occupational  exposure 
are reported to [COMPANY_007] Safety using the CT SAE Report Form.  
 
• When  an AE or SAE occurs, it is the responsibility of the investigator to review  all 
documentation (eg, hospi[INVESTIGATOR_1088], laboratory reports, and diagnostic reports) related to the event.  
• The investigator will then record all relevant AE or SAE information in the CRF.  
• It is not acceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s 
medical records to [COMPANY_007] Safety in lieu of completion of the CT SAE Report Form/AE or SAE CRF page.  Safety  Event  Recorded  on the CRF  Reported on the CT SAE 
Report Form to [COMPANY_007] Safety  Within  24 Hours of 
Awareness  
SAE All All 
Nonserious  AE All None  
Exposure to the study intervention under study during pregnancy or breastfeeding  All AEs or SAEs  associated 
with EDP or EDB  
 
Note: Instances of EDP or EDB not associated  with an 
AE or SAE  are not captured 
in the CRF  All instances  of EDP  are 
reported (whether or not 
there is an associated SAE)*  
All instances  of EDB are 
reported (whether or not there is an associated 
SAE)**  
Environmental or occupational exposure to the product under study to a nonparticipant (not involving EDP or EDB) None. Exposure to a study 
nonparticipant is not collected on the CRF The exposure (whether or 
not there is an associated AE or SAE) must be reported***  
 
Ritlecitinib (PF-0665 1600) 
Protocol B7981031 
 Final  Protocol, [ADDRESS_1061977] 2022   
PFIZER  CONFID ENTIAL  
Page  79  
  
• There may be instances w hen copi[INVESTIGATOR_773316] e 
requested by [CONTACT_161699] r Safety. In this c ase, all participant ide ntifiers , with the 
except ion of the paiiicipant number , will be redacted  on the copi[INVESTIGATOR_773317] n to Pfize r Safety.  
•  The investigator will attempt to establish a diagnosis  of the event based on signs, 
symptoms , and/or other clinical info1mat ion. Whenever possible, the diagnos is (not 
the individual signs /symptoms) will be docume nted as th e AE  or SAE.  
Assessment of Intens ity 
The investigator  will make  an assessment  of intensity for each AE and SAE  repo1ied 
during the study and assign it to 1 of th e following categor ies: 
 
• Mild: A type of AE that is usually trans ient and may req uire only minimal 
treatme nt or th erapeu tic interventio n. The event  does  not generally  interfere with 
usual AD L. 
• Moderate: A type  of AE that is usually alleviated with additio nal specific 
therapeutic interve ntion. The even t interfe res with usual ADL, causing discomfo1i , 
but poses n o significant or pennanent risk ofhann to the research paiiicipant.  
•  Severe: A type of AE  that intenupts us ual ADL, or significantly affects clinical 
status, or may req uire intensive therape utic interventio n. 
 
An event  is defined as "serious" whe n it meets at least  1 of the predefi ned outcomes as 
descr ibed in t he definit ion of an SAE , NOT when it is rated as severe.  
 
 
Assessment of Causality  
• The investigator  is obligated to assess  the relations hip between  study  interventio n 
and each occun ence of each AE or SAE. The investigator will use clinical 
judgme nt to dete 1mine t he relations hip. 
• A "reasonable possibi lity" of a relationship conveys that there are facts, evide nce, 
and/o r arguments to suggest  a causal  relationship, rather than a relationship cann ot 
be rn led out. 
• Alternative causes, such as underly ing disease(s),  concomita nt therapy,  and other 
risk facto rs, as well as the tempora l relations hip of the event  to study intervention 
administration , will be co nsidered and investig ated. 
Ritlecitinib (PF-0665 1600) 
Protocol B7981031 
 Final  Protocol, [ADDRESS_1061978] 2022   
PFIZER  CONFID ENTIAL  
Page  80  
  
• The investigator will also consult the IB an d/or prod uct infonnatio n, for marketed 
prod ucts, in their assess ment. 
• For each AE or SAE , the investigator must document in the medical  notes that they 
have reviewed t he AE  or SAE and have provi ded an  assess ment of causality. 
 
• There may be situations in which an SAE  has occm Ted an d the investigato r has 
minim al info1 mation to include in the initial repo1i to the sponsor. However , it is 
very important that the inv estigator alwa ys make an a ssessment of caus ality 
for ev ery ev ent before  the initial tran smission of the SAE data to the sponsor. 
• The investigator may change their opi[INVESTIGATOR_773318]1mat ion and send an SAE  followup repo1i with the updated  causality 
assessment. 
 
• The causality assess ment is one of the criteria used when detennining regulato1y 
repo1i ing requireme nts. 
•  If the investigator does not  know whether or not the study interve ntion caused the 
even t, then the event will be handled as "related to  study interve ntion" for repo1iing 
pmposes , as defin ed by t he sponsor. In a ddition, if the investigator deten nines that 
an SAE is associated with study proced ures, the investigator must record thi s 
causal relationship in the source documents and C RF, and report such an 
assess ment in the dedicated  section  of the CT SAE  Repo1i  Fo1m and in acco rdance 
with the SAE r epo1 iing requirements.  
 
 
Follow- Up of AEs and SAE s 
•  The investigator  is obligated to perfonn or aiTange for the conduct of suppleme ntal 
meas uremen ts and/or evaluatio ns, as medically indicated or as requested by [CONTACT_103], to elucidate the nature and/o r causality of the AE or SAE as fully as 
possible. This may inclu de addition al laborato1 y tests or investigations, 
histopat hological exainin ations, or consultation with other healthcare provi ders. 
 
• If a paiiicipant dies  during participation in the study or during a recogni zed 
follow-up perio d, the investig ator will prov ide Pfize r Safety with a copy  of any 
postmo1ie m fin dings, including histop athology  
• New  or updated  infonnation wi ll be recorded in the originally submitted 
docume nts. 
 
• The investigator will subinit  any updated SAE  data to the sponsor within 24 hours 
of receipt of the info1mation. 
Ritlecitinib (PF-0665 1600) 
Protocol B7981031 
 Final  Protocol, [ADDRESS_1061979]  
• The primaiy  mechanism for report ing an SAE  to [COMPANY_007]  Safety  will be the 
electronic DCT. 
• If the electronic system  is unavailab le, then the site will use the paper  SAE  DCT 
(see next section) to  repo1t  the event within 24 hours. 
 
• The site will enter the  SAE  data into the electron ic DCT (eg, eSAE  or PSSA)  or 
paper fonn (as applicable) as soon as t he data become availab le. 
 
•  After t he study is comp leted at  a given site, the electronic DCT  will be taken 
offline to preve nt the entiy  of new data or changes to existing data .. 
 
• If a site  receives a report of a new SAE  from  a study paiticipant o r receives updated 
data o n a previously repo1ted  SAE  after  the electi·on ic DCT  has been  taken offline , 
then the site can r epo1t this infonnation on a paper SAE fo nn (see next sect ion) or 
to [COMPANY_007] Safety by [CONTACT_756].  
 
 
SAE Reporting to [COMPANY_007] Safety via the CT SAE  Report  Form  
• Facsimile  ti-ansmission  of the CT SAE  Repo1t  Fo1m is the prefe ned method  to 
ti·ansinit this infonnation to [COMPANY_007] Safety.  
 
•  In circumstances w hen the facsimile is  not working, an alternative method  should 
be used , eg, secured (Tra nspo1t Layer Secur ity) or password -protected emai l. If 
none of these  methods  can be used,  notification by [CONTACT_9337]  a 
copy  of the CT SAE  Repo1t Fo1m sent by [CONTACT_773356] o r courie r service.  
•  Initial notification via telephone does not replace t he need  for the investigator to 
complete  and sign the CT SAE  Repo1t  Fo1m pages within  the designated  repo1ting 
time frames.  
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1061980] 2022  
PFIZER  CONFIDENTIAL  
Page  82  
 10.4. Appendix  4: Contraceptive  and Barrier Guidance  
10.4.1. Male Participant  Reproductive  Inclusion  Criteria  
 
Male participants are not required to use contraception in this study, because ritlecitinib is 
not likely  to transfer to a partner through semen  at pharmacologically  relevant  blood levels.  
 
For EU/[LOCATION_006] only:  
 
Male participants are eligible  to participate  if they agree to the following  requirements during 
the intervention period and for at least [ADDRESS_1061981] dose of study intervention, which 
corresponds to the time needed to eliminate reproductive safety risk of the study intervention(s): 
 
• Refrain  from donating sperm. 
PLUS either : 
• Be abstinent  from heterosexual  intercourse as their preferred  and usual lifestyle 
(abstinent on a long- term and persistent basis) and agree to remain abstinent.  
OR 
• Must  agree to use contraception/barrier as detailed  below:  
• Agree to use a male condom, and should also be advised of the benefit for a 
female  partner  to use a highly effective  method of contraception as a condom may 
break  or leak when  having sexual  intercourse with a WOCBP  who is not currently 
pregnant.  
10.4.2. Female  Participant  Reproductive  Inclusion  Criteria  
The criteria  below are part of inclusion  criterion  1 (Age  and Sex; Section  5.1) and specify  the 
reproductive requirements for including female participants. Refer to Section 10.4.[ADDRESS_1061982] of contraceptive methods permitted in the study.  
• A female  participant is eligible  to participate  if she is not pregnant or breastfeeding 
and at least 1 of the following conditions applies: 
• Is not a WOCBP  (see definition  in Section  10.4.3). 
OR 
• Is a WOCBP  and agrees  to use a highly  effective  contraceptive method (failure  rate of 
<1% per year) with low user dependency during the intervention period and for at l
east [ADDRESS_1061983] dose of study intervention,  which  corresponds to the time 
needed to eliminate any reproductive safety risk of the study intervention(s). The 
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1061984] dose of study intervention.  
OR 
• Is a WOCBP and agrees to use a highly effective (failure rate of <1% per year) user - 
dependent method of contraception during the intervention period and for at least [ADDRESS_1061985] dose of study intervention, which  corresponds to the time needed  to 
eliminate any reproductive safety risk of the study intervention(s). In addition to her use of the highly effective method above, she agrees to concurrently use an effective barrier method. The investigator should evaluate the effectiveness of the contraceptive method in relationship to the first dose of study intervention.  
The investigator is responsible for reviewing  the woman’s medical  history, menstrual  history, 
and recent sexual activity in order to decrease the risk of enrolling a woman with an early undetected pregnancy. 
If a female  participant  becomes pregnant during study participation,  this information  will be 
shared with her parents/legal guardians. Notification of parents/legal guardians must comply  with local regulations.  
10.4.3. Woman of Childbearing  Potential  
A woman  is considered  fertile  following menarche and until becoming postmenopausal 
unless permanently sterile (see below).  
If fertility  is unclear (eg, amenorrhea in adolescents or athletes) and a menstrual cycle cannot 
be confirmed before the first dose of study intervention, additional evaluation should be 
considered.  
Women  in th
 e following  categories are not considered  WOCBP:  
1. Premenarchal.  
2. Premenopausal  female  with 1 of the following:.  
• Documented hysterectomy;  
• Documented bilateral salpi[INVESTIGATOR_1656];  
• Documented bilateral oophorectomy.  
For individuals with permanent infertility  due to a medical  cause other than the above (eg, 
mullerian agenesis, androgen insensitivity), investigator discretion should be applied to determining study entry.  
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1061986] 2022  
PFIZER  CONFIDENTIAL  
Page  84  
 Note:  Documentation for any of the above categories can come  from the site personnel’s 
review of the participant’s medical records, medical examination, or medical history 
interview.  The method of documentation should be recorded  in the participant’s  medical 
record for the study.  
3. Postmenopausal female:  
• A postmenopausal state is defined as no menses for 12 months without an alternative 
medical cause. In addition: 
• A high FSH level in the postmenopausal range must be used to confirm a 
postmenopausal state in women  under 60 years of age and not using hormonal 
contraception or HRT. 
• A female  on HRT  and whose menopausal  status  is in doubt will be required  to use 
one of the highly effective nonestrogen hormonal contraception methods if she wishes to continue her HRT during the study. Otherwise, she must discontinue HRT to allow confirmation of postmenopausal status before study enrollment. 
10.4.4. Contraception Methods  
Contraceptive use by [CONTACT_770465]/regulations 
regarding the use of contraceptive methods for those participating in clinical trials.  
The 
following contraceptive  methods are appropriate for this study: 
Highly Effective Methods That Have Low User Dependency  
1. Implantable  progestogen-only hormone  contraception  associated  with inhibition  of 
ovulation.  
2. Intrauterine  device.  
3. Intrauterine  hormone releasing  system.  
4. Bilateral tubal  occlusion.  
5. Vasectomized  partner.  
• Vasectomized  partner is a highly effective  contraceptive method provided that the 
partner is the sole sexual partner of the WOCBP and the absence of sperm has been confirmed. If not, an additional highly effective method of contraception should be used. The spermatogenesis cycle is approximately 90 days. 
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1061987] 2022  
PFIZER  CONFIDENTIAL  
Page  85  
 Highly Effective  Methods That Are User  Dependent  
6. Combined (estrogen - and progestogen-containing) hormonal contraception associated 
with inhibition of ovulation: 
• Oral + barrier*  
• Intravaginal + barrier*  
• Transdermal  + barrier*  
7. Progestogen-only hormone contraception  associated  with inhibition of ovulation:  
• Oral + barrier*  
• Injectable  + barrier*  
8. Sexual Abstinence  
Sexual abstinence is considered a highly effective method only if defined as 
refraining from heterosexual intercourse during the entire period of risk associated with the study  intervention. The reliability  of sexual  abstinence needs to be evaluated 
in relation to the duration of the study and the preferred and usual lifestyle of the participant.  
* Acceptable barrier  methods to be used concomitantly with options 6 or 7 for the study 
include any of the following:  
• Male or female condom, with or without spermicide  (male  condom and female 
condoms should not be used together due to risk of failure with friction); 
• Cervical cap, diaphragm, or sponge with spermicide.  
• A combination of male  condom with either cervical  cap, diaphragm, or sponge 
with spermicide (double- barrier methods).  
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1061988] 2022  
PFIZER  CONFIDENTIAL  
Page  86  
 10.5. Appendix  5: Liver  Safety: Suggested Actions  and Follow- Up Assessments 
Potential Cases of Drug -Induced Liver Injury  
Humans exposed to a drug who show no sign of liver injury (as determined by [CONTACT_20023])  are termed  “tolerators,” while  those  who show transient  liver injury  but adapt 
are termed “adaptors.” In some participants, transaminase elevations are a harbinger of a 
more serious potential outcome. These participants fail to adapt and therefore are “susceptible” to progressive and serious liver injury, commonly referred to as DILI. Participants who experience a transaminase elevation above 3 × ULN should be monitored more frequently to determine if they are “adaptors” or are “susceptible.”  
In the majority of DILI cases, elevations in  AST and/or  ALT precede T bili elevations (>2 × 
ULN)  by [CONTACT_749835].  The increase  in T bili typi[INVESTIGATOR_773319]/ALT is/are 
still elevated  above 3 × ULN  (ie, AST/ALT  and T bili values  will be elevated  within  the same 
laboratory sample). In rare instances, by [CONTACT_29623] T bili elevations are detected,  AST/ALT 
values might have decreased.  This occurrence is still regarded  as a potential DILI.  Therefore, 
abnormal elevations in either  AST  OR ALT  in addition  to T bili that meet  the criteria  outlined 
below are considered  potential DILI  (assessed  per Hy’s  law criteria) cases and should always 
be considered important medical events, even before all other possible causes of liver injury have been excluded. 
The threshold of laboratory abnormalities for a potential DILI case depends on the 
participant’s  individual baseline values  and underlying conditions. Participants  who present 
with the following laboratory abnormalities should be evaluated further as potential DILI (Hy’s law) cases to definitively determine the etiology of the abnormal laboratory values:  
• Participants  with AST/ALT and T bili baseline values within  the normal range who 
subsequently present with AST OR ALT values ≥3 × ULN AND a T bili value  
≥2 × ULN  with no evidence of hemolysis  and an alkaline phosphatase value  
<2 × ULN or not available.  
• For participants  with baseline AST  OR ALT  OR T bili values  above the ULN,  the 
following threshold values are used in the definition mentioned above, as needed, depending on which values are above the ULN at baseline: 
• Preexisting AST or ALT baseline values above the normal range: AST or ALT values ≥2 times  the baseline values AND  ≥3 
× ULN;  or ≥8 × ULN  (whichever is 
smaller).  
• Preexisting  values of T bili above the normal range:  T bili level  increased  from 
baseline value by [CONTACT_219911] ≥1 × ULN or if the value reaches ≥3 × ULN (whichever is smaller).  
Rises in  A
ST/ALT and T bili separated by [CONTACT_726] a few weeks should be assessed individually  based  on clinical  judgment; any case where  uncertainty  remains  as to whether it 
represents a potential Hy’s law case should be reviewed with the sponsor..  
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1061989] and  ALT and T bili for suspected Hy’s law 
cases, additional laboratory tests should include albumin, CK, direct and indirect bilirubin, 
GGT, PT/INR, total bile acids, and alkaline phosphatase. Consideration should also be given to drawing a separate tube of clotted blood and an anticoagulated tube of blood for further testing, as needed, for further contemporaneous analyses at the time of the recognized initial abnormalities to determine etiology.  A detailed history, including relevant information, such 
as review of ethanol, acetaminophen/paracetamol (either by [CONTACT_20025] a coformulated product in prescription or over-the-counter medications), recreational drug, or supplement (herbal) use and consumption, family  history, sexual  history, travel history,  history  of contact 
[CONTACT_4490] a jaundiced person, surgery, blood transfusion, history of liver or allergic disease, and potential occupational exposure to chemicals, should be collected. Further testing for acute hepatitis  A, B, C, D, and E infection,  liver imaging  (eg, biliary  tract),  and collection  of serum 
samples for acetaminophen/paracetamol  drug and/or protein  adduct levels may be warranted.  
All cases demonstrated on repeat testing as meeting the laboratory  criteria of AST/ALT and 
T bili elevation defined above should be considered potential DILI (Hy’s law) cases if no other reason  for the LFT abnormalities  has yet been  found. Such potential DILI  (Hy’s  law) 
cases are to be reported as SAEs, irrespective of availability of all the results of the investigations performed to determine etiology of the LFT abnormalities.  
A potential DILI (Hy’s law) case becomes a confirmed case only after all results of 
reasonable investigations  have been  received  and have excluded  an alternative  etiology.  
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1061990] 2022  
PFIZER  CONFIDENTIAL  
Page  88  
 10.6. Appendix  6: Kidney  Safety  Monitoring  Guidelines  
10.6.1. Laboratory Assessment  of Change  in Kidney  Function and Detection  of Kidney 
Injury  
Standard kidney safety  monitoring requires assessment of baseline and postbaseline serum 
creatinine  (Scr measurement  to estimate  creatinine clearance  normalized  to BSA [Modified 
Schwartz eCrCl]).  
Regardless of whether kidney function monitoring tests are required as a routine safety 
monitoring  procedure in the study, if the investigator or sponsor deems it necessary  to further 
assess kidney safety and quantify kidney function, then these test results should be managed and followed per standard of care. 
10.6.2. Age-Specific  Kidney  Function Calculation  Recommendation  
Modified Schwartz equation (pediatric  patients 2 to <12 years of age).  
• CrCl  (mL/min/1.73  m
2) = (K*Ht)/Scr 
• Height (Ht) in cm;  serum  creatinine  (Scr) in mg/dl  
• K (proportionally  constant):  
• Female  child:  K = 0.55 
• Male child: K = 0.70 
10.6.3. Adverse Event  Grading  for Kidney  Safety  Laboratory Abnormalities  
AE grading for decline in kidney function (ie, eGFR or eCrCl)  will be according to 
KDIGO criteria.  
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1061991] 2022  
PFIZER  CONFIDENTIAL  
Page  89  
 10.7. Appendix  7: Prohibited Concomitant Medications That  May Result  in DDI 
This is not an all -inclusive list. This list of drugs prohibited for potential DDI concerns with 
the IP may be revised during the course of the study with written notification from sponsor, 
to include or exclude specific drugs or drug categories  for various reasons  (eg, emerging DDI 
results for the IP, availability of new information in literature on the DDI potential of other drugs).  
Study personnel should stay current and consult with their pharmacy to exclude all concomitant medications that are moderate to potent CYP3A inducers or sensitive or moderate  sensitive  CYP3A substrates  or sensitive or moderate  sensitive  CYP1A2  substrates. 
If a medication is a sensitive or moderate sensitive CYP3A substrate, or a sensitive or moderate sensitive CYP1A2 substrate, and is not listed in Table [ADDRESS_1061992]. John’s  Wortd 
  Talviraline  
a. Sensitive  CYP3A  substrates  are drugs  that demonstrate  an increase in AUC  of ≥5-fold with strong 
index inhibitors of a given metabolic pathway in clinical DDI studies.  
b. Moderate  sensitive  substrates  are drugs  that demonstrate  an increase  in AUC  of ≥2 to <5-fold. 
c. All prohibited drugs that are CYP3A inducers require at least a 28 day or 5 half -lives (whichever is 
longer) washout prior to the first dose of study intervention. In a situation where appropriate medical care of a participant requires the use of a prohibited CYP3A inducer: Moderate to potent inducers of CYP3A are not permitted in the study EXCEPT in emergency situations.  Note: Mitotane is not 
permitted for any duration due to its long half -life; however, if necessary mitotane may be used in an 
emergency,  however  the participant  will then be discontinued  from  the study.  Topi[INVESTIGATOR_2855]  (including  skin or 
mucous membranes) application of antimicrobial and antifungal medications is permitted.  
d. Notated  as potent  inducers.  
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1061993]  
Sensitive substrates are drugs that demonstrate an increase in AUC of ≥[ADDRESS_1061994]  in clinical  DDI studies. Topi[INVESTIGATOR_2855]  (including  skin or mucous 
membranes) application of antimicrobial and antifungal medications is permitted.  
Moderate  sensitive  substrates  are drugs  that demonstrate  an increase  in AUC  of ≥2 to <[ADDRESS_1061995] label  for any other medication  used during the study 
for information regarding medication that is prohibited for concomitant use.  
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1061996] 2022  
PFIZER  CONFIDENTIAL  
Page  91  
 10.8. Appendix  8: Country -Specific  Requirements  
10.8.1. [LOCATION_009]  
Contrat Unique  
1. GCP  Training  
Before enrolling any participants, the investigator and any sub- investigators will 
complete the [COMPANY_007]- provided Good Clinical Practice training course (“[COMPANY_007] GCP 
Training”) or training  deemed  equivalent by [CONTACT_4618].  Any investigators  who later join 
the study will do the same before performing study- related duties. For studies of 
applicable duration, the investigator and sub- investigators  will complete  [COMPANY_007]  GCP 
Training or equivalent every [ADDRESS_1061997],  and of any serious breaches of this protocol or of ICH GCP  that 
the investigator becomes aware of.  
4. Termination  Rights  
[COMPANY_007]  retains the right to discontinue development of ritlecitinib  at any  time.  
10.8.2. Japan  
[IP_ADDRESS]. Reporting  Requirements  
When becoming aware of any defect in an investigational product that meets the following conditions, the investigator must report it to the clinical trial sponsor within 24 hours (see Section  [IP_ADDRESS]).  Note:  Such  reporting of a defect  in an investigational product does not alter 
the AE reporting process described in Appendix 3. 
• A defect  that, directly  or indirectly, resulted  in an SAE  (see Section  10.3.2) observed 
in a study participant, user, or other person 
OR 
• A defect  related  to an investigational  product whose recurrence might lead to death  or 
serious deterioration in health  
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1061998] 2022  
PFIZER  CONFIDENTIAL  
Page  92  
 For reporting  of complaints  concerning quality of investigational products not meeting  the 
reporting requirements above, see the detailed procedure in the “Complaints concerning 
investigational products” section of the IPM. 
[IP_ADDRESS]. Reporting  Procedure  
The procedure for reporting of defects in study interventions to the sponsor should be agreed 
upon in advance for each study by [CONTACT_773357].  
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1061999] 2022  
PFIZER  CONFIDENTIAL  
Page  93  
 10.9. Appendix  9: Hepatitis  B testing  algorithm and full eligibility  criteria  
 
For participants in countries in which hepatitis B prevalence has been reported at a 
rate of >5.0%* or if required  by [CONTACT_26269],  participants  will be  tested  as 
follows:  
 
At screening,  HBsAg  and HBcAb  will be tested:  
a. If both tests  are negative,  the participant is eligible  for study inclusion.  
b. If HBsAg is positive, the participant must be excluded from participation in the study.  
c. If HBsAg  is negative and HBcAb  is positive,  HBsAb  and HBVDNA reflex  testing  is 
required:  
• If HBsAb  is negative,  the participant must be excluded from participation  in the 
study;  
• If HBVDNA is detected,  the participant must be excluded from  participation  in the 
study;  
• If HBsAb  is positive  and HBVDNA is undetectable,  the participant is eligible  for 
study inclusion. 
In all other countries, participants will be tested as follows: 
At screening, HBsAg and HBcAb will be tested:  
 
a. If both tests  are negative,  the participant is eligible  for study inclusion.  
b. If HBsAg  is positive,  the participant  must be excluded from participation  in the 
study.  
c. If HBsAg is  negative and  HBcAb is  positive, HBsAb  reflex testing is  required:  
• If HBsAb  is negative,  the participant must be excluded from participation  in the 
study;  
• If HBsAb  is positive,  the participant  is eligible  for study inclusion. If the participant is 
included in the study, for subsequent visits no hepatitis B testing is required. 
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1062000] 2022  
PFIZER  CONFIDENTIAL  
Page  94  
 10.10. Appendix 10 – SALT 
Diagnosis of AA must be performed  by a qualified  dermatologist (board certified  or 
equivalent) who has experience with AA.  
SALT is a quantitative assessment of alopecia severity  based on scalp terminal hair loss.  
Score parameters utilize a visual aid showing the division of the scalp hair into four 
quadrants (back, top of scalp, and both sides), with each of the four quadrants given an accurate determination  of the % of scalp  surface area covered, representing 24%, 40%, 18%, 
and 18% of the total scalp surface area, respectively. 
The overall SALT score will  be collected  at the  Screening Visit,  for eligibility  purposes. 
The assessment  will be performed  by a qualified  dermatologist (board  certified  or equivalent) 
who has experience with AA or a delegated member of the study staff ( an experienced and 
qualified physician or healthcare professional) . 
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1062001] 2022  
PFIZER  CONFIDENTIAL  
Page  95  
 10.11. Appendix  11 – C- SSRS 
Suicidal Ideation and Behavior will be assessed at Screening using the C- SSRS (Columbia 
Suicide Severity  Rating  Scale – pediatric  version, baseline assessment)  version  for pediatric 
patients 6 to 11 years old. 
There are 2 versions of the C -SSRS - “C -SSRS for screening and baseline visits” and “C- 
SSRS for any post-baseline visits”.  In this study, only the baseline version will be used, for 
eligibility purposes.  
The person conducting the  assessment must be either: 
a. A Mental  Health  Professional  or 
b. A study staff member  with appropriate training  and certification  (Completion  of 
training curriculum as required by [CONTACT_773358])  
Participants  who had previous history  of suicidal behaviors in the past 5 years (“Yes” answer 
for events that occurred in the past 5 years) to any of the suicidal behavior items of the  
C-SSRS  or any lifetime  history  of serious or recurrent  suicidal  behavior, a risk assessment 
must be performed and documented by a qualified mental health professional to assess 
whether it is safe for the participant to participate in the trial.  
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1062002] 2022  
PFIZER  CONFIDENTIAL  
Page  96  
 10.12. Appendix  12 – CDRS -R 
The CDRS -R is a brief 17 -item rating scale for diagnosing depression and assessing its 
severity.  The scale is designed for use in 6- to 12-year-old children. Individuals are rated  on 
seventeen symptom areas, including dysfunction relating to schoolwork, interpersonal 
relationships, psychosomatic complaints, and other thoughts and feelings commonly presenting in depressed children and adolescents. Scores are determined by a clinician through a semi -structured  interview  with the child  and parent.
39 Interviews  take about 10-15 
minutes to complete and score. Each item score ranges from 1 to 5 or 1 to 7. Possible total scores ranging from 17 to 113. 
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1062003] 2022  
PFIZER  CONFIDENTIAL  
Page  97  
 10.13. Appendix  13.1 – PROMIS® Parent  Proxy Short  Form  v2.0 – Anxiety  8a 
The PROMIS Parent Proxy  Short Form v2.0 – Anxiety 8a is an [ADDRESS_1062004] possible raw score is 40. Raw scores are transformed to  
T-scores using a conversion table  available  from the developer.40 
T-score rescales the raw score into a standardized score with a mean of 50 and a SD of 10. 
Therefore, a person with a T -score of 60 is one SD above the pediatric population mean, and 
a T-Score of 70 is two SDs above the pediatric population mean of 50. PROMIS T- scores 70 
or greater  are considered  severe dysfunction; T- scores from 60 to 69 are considered  moderate 
dysfunction (PROMIS 2020a).40 
10.13.1. Appendix  13.2 – PROMIS® Parent  Proxy Short  Form  v2.0 – Depressive 
Symptoms 6a 
The PROMIS  Parent  Proxy  Short Form  v2.0 – Depressive Symptoms 6a is a 6-item measure 
of depressive symptoms. Each item has five response options ranging in value from [ADDRESS_1062005] possible raw score is 40. Raw 
scores are transformed to T -scores using a conversion table available from the developer.  
40 
T-score rescales the raw score into a standardized score with a mean of 50 and a SD of 10. 
Therefore, a person with a T -score of 60 is one SD above the pediatric population mean, and 
a T-Score of 70 is two SDs above the pediatric population mean of 50. PROMIS T- scores 70 
or greater  are considered  severe dysfunction; T- scores from 60 to 69 are considered moderate 
dysfunction (PROMIS 2020a). 40 
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1062006] 2022  
PFIZER  CONFIDENTIAL  
Page  98  
 10.14. Appendix 14 - BRIEF®2  
The BRIEF®2,  that will be used in this study is an ObsRO parent/caregiver completed scale 
designed to assess executive behaviors  in children  and adolescents.  The BRIEF®2  evaluates 
neuropsychological development and executive functions in adolescents. The BRIEF®2 
scales assess how well the child is demonstrating behavioral or emotional control, initiating activity,  engaging in planful and well-organized  problem solving, and monitoring one’s  own 
social success and problem -solving outcomes.  
The BRIEF®2 consists of 63 items and yields scores on nine scales, with the Inhibit and Self-Monitor scales comprising the BRI, the Shift and Emotional Control scales comprising 
the ERI, and the Initiate,  Working Memory, Plan/Organize,  Task  Monitor, and Organization 
of Materials scales comprising the CRI. The questionnaire will be completed by [CONTACT_7071]/caregiver of the participant.
41 
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1062007] 2022  
PFIZER  CONFIDENTIAL  
Page  99  
 10.15. Appendix  15 - Modified  CDLQI  
The CDLQI  is a children’s  version of the DLQI.[ADDRESS_1062008]  of 10 items  that assess 
participant health related quality of life (daily activities, personal relationships, symptoms 
and feelings, leisure, work and school, and treatment). The CDLQI assesses quality of life over the last week. In this modified version, all items were modified to refer to “alopecia areata” instead of “skin” or “skin trouble”.  
 
Each  item is scored  from  0 to 3. Questions left unanswered  are given a score  of 0. Item 
scores are summed and expressed as usual out of a maximum score of 30.  
The questionnaires are self-explanatory and can be handed to the participant who is asked  to 
fill them in with the help of the child’s parent or guardian, as necessary. 
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1062009] 2022  
PFIZER  CONFIDENTIAL  
Page  100  
 10.16. Appendix  16 - WISC -V 
The WISC -V is clinical measure of cognitive ability/intelligence  of children  6 to 16 years of 
age. Responses from the WISC -V can be used to calculate  scores for intellectual functioning 
in several cognitive domains, as well as a composite score that represents the general 
intellectual ability.  
The WISC -V is composed of multiple  subtests and index scales,  with each subtests grouped 
into three general categories of index scales: primary, ancillary, and complementary.  
Administration of the primary subtests is recommended for a comprehensive description of intellectual ability.  The ancillary  and complementary  subtests can be administered  in addition 
to the primary subtests to provide a broader sampling of intellectual functioning and to yield more information.  
This assessment  will be administered  by [CONTACT_1716][INVESTIGATOR_1660] [INVESTIGATOR_1660] a delegated  member of 
the study  staff. Administration  and Scoring Manual,  Technical  and Interpretive  Manual  will 
be provided to the sites.
43 
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1062010] 2022  
PFIZER  CONFIDENTIAL  
Page  101  
 10.17. Appendix  17: Abbreviations  
The following is a list of abbreviations  that may  be used  in the protocol.  
 
Abbreviation  Term  
A1 to A3 albuminuria  (KDIGO  albuminuria  severity  standardization)  
AA alopecia  areata  
Abs absolute  
ADL  activity/activities  of daily  living  
AE adverse  event  
AESI  adverse  event of  special interest  
AKI acute kidney  injury  
ALT  alanine aminotransferase  
AST aspartate aminotransferase  
AT alopecia  totalis  
AU alopecia  universalis  
AUC  Area  under  the concentration -time curve  
AUC tau area under  the concentration -time curve  from  time zero to the end of 
the dosing interval  
AxMP  auxiliary  medicinal product  
BID twice  daily  
BP blood  pressure  
BRI Behavior Regulation Index  
BRIEF  Behavior  Rating  Inventory  of Executive  Function  
CDLQI  Children's Dermatology  Life Quality  Index  
CDRS -R Childhood  Depression  Rating  Scale  – Revised  
CFR Code of Federal Regulations  
CIOMS  Council  for International  Organizations  of Medical  Sciences  
CMV  cytomegalovirus  
CONSORT  Consolidated  Standards  of Reporting  Trials  
COVID -[ADDRESS_1062011] research organization  
CSR Clinical Study  Report  
C-SSRS  Columbia  – Suicide Severity  Rating Scale  
CTCAE  Common Terminology  Criteria for Adverse Events  
CTIS  Clinical  Trial  Information  System  
CVEAC  Cardiovascular  Event  Adjudication  Committee  
CYP  cytochrome  P450  
CYP1A2  cytochrome P450 family  [ADDRESS_1062012]  data collection  tool 
DDI drug-drug interaction  
DILI  drug-induced  liver injury  
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1062013]  European  Union  Drug  Regulating  Authorities  Clinical  Trials 
(European Clinical Trials Database)  
FACS  Fluorescence -Activated  Cell Sorting  
FDA  Food  and Drug Administration  
FSH follicle -stimulating  hormone  
F/U follow -up 
G1 to G5 Grade (KDIGO eGFR category  standardization)  
GCP  Good  Clinical  Practice  
GGT  gamma -glutamyl  transferase  
HBcAb  hepatitis  B core antibody  
HBsAb  hepatitis B surface antibody  
HBsAg  hepatitis B surface antigen  
HBVDNA  Hepatitis  B Virus  Deoxyribonucleic  acid 
HIPAA  Health  Insurance Portability  and Accountability  Act 
HIV human  immunodeficiency  virus  
HR heart  rate 
HRQoL  health -related  quality  of life 
HRT  hormone  replacement  therapy  
Ht height  
IB Investigator’s  Brochure  
ICD informed  consent  document  
ICH International  Council  for Harmonisation  of Technical  Requirements 
for Pharmaceuticals for Human Use  
ID identification  
IFN interferon  
IMP investigational  medicinal  product  
IND Investigational  New  Drug  
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1062014]  
IV intravenous(ly)  
JAK Janus kinase  
K Proportionality  constant  for Bedside  and Modified  Schwartz 
Equations (kidney function)  
K2EDTA  Dipotassium  ethylenediaminetetraacetic  acid 
KDIGO  Kidney  Disease: Improving  Global  Outcomes  
LFT liver function  test 
LPD local  product  document  
MAC  Malignancy  Adjudication Committee  
MMF  mycophenolate  mofetil  
MQI  medically  qualified individual  
MRHD  maximum recommended human dose 
MTX  methotrexate  
NA not applicable  
NIMP  noninvestigational  medicinal  product  
NK natural  killer  
NSEAC  Neurosafety  Event  Adjudication  Committee  
ObsRO  observer -reported  outcomes  
OIRC  Opportunistic  Infection  Review  Committee  
PD pharmacodynamic(s)  
PGI-C Patient’s  global  impression  of change  
PI [INVESTIGATOR_773320](s)  
PR pulse  rate 
PSSA  [COMPANY_007]'s  Serious  Adverse  Event  Submission  Assistant  
PT prothrombin time 
QD once  daily  
QFT QuantiFERON  test 
QoL quality  of life 
qual qualitative  
RBC  red blood  cell 
RNA  ribonucleic  acid 
SAE serious  adverse  event  
SALT  Severity  of Alopecia Tool 
SAP Statistical  Analysis  Plan 
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1062015] 2022  
PFIZER  CONFIDENTIAL  
Page  104  
  
Abbreviation  Term  
SC subcutaneous(ly)  
Scr serum creatinine  
SoA schedule  of activities  
SOP standard operating procedure  
SRSD  Single Reference Safety  Document  
S[LOCATION_003]R  Suspected  Unexpected  Serious  Adverse  Reaction  
TB tuberculosis  
T bili total bilirubin  
TBV  total blood  volume  
TEAE  Treatment  emergent  adverse  event  
TH1 type [ADDRESS_1062016] infection  
WBC  white  blood  cell 
WHO  World  Health  Organization  
WISC -V Wechsler  Intelligence  Scale  for Children  - 5th edition  
WOCBP  woman/women  of childbearing  potential  
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1062017] 2022  
PFIZER  CONFIDENTIAL  
Page  105  
 11. REFERENCES  
 
 
 
1 Hordinsky M, Donati A. Alopecia areata:  an evidence- based  treatment  update. Am J 
Clin Dermatol. 2014;15(3):231–46. 
2 Hordinsky MK. Current Treatments  for Alopecia Areata.  J Investig Dermatol  Symp. 
2015;17(2):44– 6. 
3 Messenger  AG, McKillop  J, Farrant  P, et al. British  Association  of Dermatologists' 
guidelines for the management of alopecia areata 2012. Br J Dermatol. 
2012;166(5):916– 26. 
4 Alkhalifah  A, Alsantali  A, Wang  E, et al. Alopecia areata update: part II – treatment. 
J Am Acad Dermatol. 2010;62(2):191–204. 
[ADDRESS_1062018] Rev. 2008;(2):CD004413. 
6 Crispin MK, Ko JM, Craiglow BG, et al. Safety and efficacy of the JAK inhibitor tofacitinib  citrate in  patients with  alopecia areata.  JCI Insight. 2016;1(15):e89776.  
7 Kassira S, Korta  DZ, Chapman  LW, et al. Review  of treatment for alopecia totalis  and 
alopecia universalis. Int J Dermatol. 2017;56(8):801–10. 
8 Liu LY, Craiglow BG, Dai F, et al. Tofacitinib for the treatment of severe alopecia areata and variants: A study  of 90 patients. J Am Acad Dermatol. 2017;76(1):22– 8. 
9 Gilhar A, Etzioni A, Paus  R. Alopecia areata. N  Engl J Med. 2012;366(16):1515– 25. 
10 Hordinsky MK. Overview of alopecia areata.  J Investig Dermatol  Symp  Proc.  2013; 
16(1):S13– 5. 
11 Gilhar A. Collapse of immune privilege  in alopecia areata:  coincidental or substantial? J 
Invest Dermatol. 2010;130(11):2535–7. 
[ADDRESS_1062019] 
cells and CD8+ T -cells may contribute to the pathogenesis of alopecia areata. PLoS 
ONE 2014;9(5):e94260. 
13 Suárez- Fariñas  M, Ungar B, Noda S, et al. (2015). Alopecia areata profiling  shows TH1, 
TH2, and IL-23 cytokine activation without parallel TH17/TH22 skewing. J Allergy Clin Immunol. 2015;136(5):1277–87.  
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1062020] 2022  
PFIZER  CONFIDENTIAL  
Page  106  
  
 
 
 
14 NAAF  website at http:///www.naaf.org. Accessed:  14 Mar 2018.  
15 Tosti  A, Bellavista  S, Iorizzo  M. Alopecia areata:  a long term follow -up study of 191 
patients. J Am Acad Dermatol. 2006;55:438–41. 
16 Trüeb RM, Dias MFRG. Alopecia Areata: a Comprehensive Review of Pathogenesis 
and Management.  Clin Rev Allergy  Immunol. 2018;54(1):68-87. doi:10.1007/s12016- 
017-8620-9 
17 Alkhalifah A. Alopecia areata update. Dermatol Clin 2013;31:93– 108. 
[ADDRESS_1062021]  of alopecia.  BMJ. 2005;331(7522):951 –3. 
[ADDRESS_1062022] 2001;9:283–9. 
20 Colon EA, Popkin MK, Callies  AL, et al. Lifetime  prevalence of psychiatric disorders  in 
patients with alopecia areata. Comp Psychiatry 1991;32:245–51. 
21 Ruiz -Doblado S, Carrizosa  A, García-Hernández MJ. Alopecia areata:  psychiatric 
comorbidity and adjustment to illness. Int J Dermatol. 2003;42:434–7. 
22 Chen  W, Mempel  M, Traidl- Hofmann  C, et al. Gender aspects in skin diseases.  J Eur 
Acad Dermatol Venereol. 2010;24:1378–1385. 
23 Sellami R, Masmoudi J, Ouali  U, et al. The relationship between  alopecia areata and 
alexithymia, anxiety and depression: A case-control study. Indian J Dermatol. 2014;59(4):421.  
24 Fricke  ACV,  Miteva M. Epi[INVESTIGATOR_773321]:  a systematic 
review. Clin Cosmet Investig Dermatol. 2015; 8:397–403. 
25 Liakopoulou M, Alifieraki T, Katideniou A, et al. Children with alopecia areata: 
psychiatric symptomatology and life events.  J Am Acad  Child  Adolesc Psychiatry. 
1997;36(5):678– 84. 
26 Dubois M, Baumstarck -Barrau  K, Gaudy- Marqueste C, et al. Quality  of life in alopecia 
areata: a study of [ADDRESS_1062023] Dermatol 2010;130: 2830–3. 
27 Ghajarzadeh  M, Ghiasi  M, Kheirkhah S. Associations between  skin diseases and quality 
of life: a comparison of psoriasis, vitiligo, and alopecia areata. Acta Medica Iranica. 2012;50(7):511– 5. 
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1062024] 2022  
PFIZER  CONFIDENTIAL  
Page  107  
  
 
 
 
28 Masmoudi J, Sellami R, Ouali  U, et al. Quality  of Life in Alopecia Areata:  A Sample  of 
Tunisian Patients. Dermatol Res Pract. 2013; 2013:983804. 
[ADDRESS_1062025], Brasil  MA, et al. Quality  of life in alopecia areata:  a case- 
control study. Int J Trichology. 2014;6(1):8–12. 
30 Baghestani  S, Zare S, Seddigh SH. Severity  of depression and anxiety in patients with 
alopecia areata in Bandar Abbas, Iran. Dermatol Reports. 2015;7(3):6063. 
31 Jankovic S, Perić  J, Maksimović N, et al. Quality  of life in patients with alopecia areata: 
a hospi[INVESTIGATOR_307]- based cross- sectional study. J Eur Acad Dermatol Venereol.  
2016;30(5):840- 6. 
32 Rencz F, Gulácsi  L, Péntek  M, et al. Alopecia areata and health -related  quality  of life: a 
systematic review and meta-analysis. Br J Dermatol. 2016;175(3):561–71.  
33  Zhang M, Zhang N. Quality of life assessment in patients with alopecia areata and 
androgenetic alopecia in the People's Republic of China. Patient  Prefer  Adherence. 
2017;11:151 –5. 
34 NAAF  website.  Available  from:  https://www.naaf.org/alopecia- areata/alopecia -areata - 
and-emotional- wellness -in-children. Accessed: [ADDRESS_1062026] 2017;3:115–8. 
36  Craiglow  BG, Liu LY, King  BA. Tofacitinib  for the treatment of alopecia areata  and 
variants in adolescents. J Am Acad Dermatol 2017;76:29–32. 
37 General Clinical Pharmacology  Considerations for Pediatric Studies for Drugs and 
Biological Products; Guidance for Industry; U.S. Department  of Health  and Human 
Services Food and Drug Administration Center for Drug Evaluation and Research 
(CDER); December 2014 Clinical Pharmacology. Available from: https://www.fdanews.com/ext/resources/files/12 -14/12- 08-14- 
pediatricguidance.pdf?[PHONE_16119]. Accessed: 24 Sep 2022. 
38 Wang, Y., Jadhav PR, Lala M. et al.. "Clarification on Precision Criteria to Derive 
Sample  Size When  Designing Pediatric  Pharmacokinetic Studies  " J Clin Pharmacol, 
2012; 52: 1601-6. 
Ritlecitinib  (PF-06651600) 
Protocol B7981031  
Final  Protocol,  [ADDRESS_1062027] 2022  
PFIZER  CONFIDENTIAL  
Page  108  
  
 
 
 
39 (CDRS -R) Children's Depression Rating Scale, Revised. Available from: 
https://www.wpspublish.com/cdrs -r-childrens -depression -rating -scale- revised. 
Accessed: 24 Sep 2022. 
40  PROMISa.  PROMIS  measures are scored  on the T- score metric.  High  scores mean  more 
of the concept being measured.  Available at: https://www.healthmeasures.net/score -and- 
interpret/interpret-scores/promis. Accessed: [ADDRESS_1062028] 2020. 
41 Gioia,  G.A.,  Isquith, PK., Guy, S C.,et al. Behavior  Rating  Inventory of Executive 
Function; 2000. 
42 Lewis -Jones MS, Finlay  AY. The Children’s  Dermatology  Life Quality  Index (CDLQI): 
Initial validation and practical use. Br J of Dermatol, 1995; 132: 942 -9. 
43 Gienger, Claudia Angelika. Wechsler  Intelligence  Scale  for Children  – Fifth  Edition 
(WISC -V). Verlag Hans Huber; 2018 